OPTN/SRTR 2024 Annual Data Report: Kidney

Krista L. Lentine^1,2, Jodi M. Smith^1,3, Grace R. Lyden^1,4, Jonathan M. Miller^1,4, Sarah E. Booker⁵, Thomas G. Dolan⁵, Dzhuliyana Handarova⁵, Samantha Weiss⁵, Kayla R. Temple⁵, Jon J. Snyder^1,4,6, Allyson Hart^1,4

¹Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN

²SSM Health Saint Louis University Hospital Transplant Center, Saint Louis University School of Medicine, St. Louis, MO

³Department of Pediatrics, University of Washington, Seattle, WA

⁴Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, MN

⁵Organ Procurement and Transplantation Network, United Network for Organ Sharing, Richmond, VA

⁶Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

Abstract

In 2024, the field of kidney transplantation faced both notable successes and ongoing challenges. A record 27,660 kidney transplants were performed in the United States, an achievement driven largely by deceased donor kidney transplant (DDKT) growth, although with only a modest increase from 27,351 kidney transplants in 2023. The number of adult candidates listed for kidney transplant rose to 143,982 (approaching the prepandemic peak of 2019), with 10.7% of candidates waiting 5 years or longer. Transplant counts increased across Black, Hispanic, Asian, and Multiracial recipients, with the largest gains in DDKT rates among Black patients, following the Organ Procurement and Transplantation Network’s January 2023 policy change to modify waiting time for candidates affected by race-inclusive estimated glomerular filtration rate calculations. After increases in mortality during the COVID-19 pandemic, pretransplant death rates generally declined in 2024 across age, race and ethnicity, sex, and blood type, although substantial geographic variation persisted by donation service area. At the same time, the proportion of deceased donor kidneys recovered for transplant but not transplanted rose to 29.3%, with even higher rates for biopsied kidneys (40.8%), those from donors aged 65 years or older (68.9%), and kidneys with a kidney donor profile index of 85% or greater (69.5%). In contrast, nonuse of kidneys from hepatitis C virus–positive donors (antibody positive/nucleic acid test negative) declined to 32.2% in 2024 from 49.5% in 2016, in parallel with broader use of direct-acting antiviral therapy protocols. Disparities in access to living donor kidney transplant (LDKT) remain and particularly affect non-White and publicly insured patients. Rates of delayed graft function, which had risen steadily over the past decade, appear to have plateaued at 26.7% overall for adult recipients in 2024. Long-term outcomes continue to favor living donor kidneys, with 5-year graft survival of 89.9% for LDKT versus 82.5% for DDKT among recipients aged 18-34 years, and 79.8% versus 66.1% among those aged 65 years or older for transplants in 2017-2019. In 2024, the number of pediatric candidates added to the kidney transplant waiting list reached its highest point at 1,232. The total number of pediatric kidney transplants performed increased to a new high of 832 in 2024; 601 (72.2%) were DDKTs and 231 (27.8%) were LDKTs. This increase was driven by growth in pediatric DDKT; the annual number of pediatric LDKTs has been steady since 2013.

Keywords: Deceased donor transplant, kidney transplantation, living donor transplant, transplant access, transplant outcomes, waitlist outcomes

1 Introduction

For eligible patients with end-stage kidney disease, kidney transplant offers the greatest potential for long-term survival without dialysis, while also representing the most cost-effective kidney failure treatment modality for the health care system. Nonetheless, persistent challenges remain in improving equitable access to transplant, optimizing both deceased and living donation, and enhancing long-term allograft survival. In the post–COVID-19 era, attention has turned toward modernizing the transplant system to improve performance and efficiency. While the number of deceased donor kidney transplants (DDKTs) continues to rise, the pace of growth in 2024 was slower than in recent years, and progress is tempered by rising kidney nonuse rates, longer cold ischemia times, and higher rates of delayed graft function under broader geographic organ-sharing policies. Living donor kidney transplant (LDKT) rates showed a modest increase in 2024 but generally remain low and are characterized by lower access among non-White and publicly insured patients.

This chapter in the Annual Data Report provides a comprehensive overview of the current state of kidney transplantation in the United States and presents detailed data on adult and pediatric waiting lists, deceased and living donation, transplant procedures, and outcomes. Key achievements, as well as concerns that warrant close attention, are highlighted. A growing concern for kidney transplant is allocation out of OPTN sequence (AOOS); the analytic definition of AOOS was finalized in June 2025, and these data will be included in the 2025 Annual Data Report.

2 Adult Kidney Transplant

2.1 Waiting List

Following a decline to 37,401 adult additions to the kidney transplant waiting list in 2020 due to the COVID-19 pandemic, the number of new candidates has increased annually and reached a record 49,249 in 2024 (Figure KI 1). The total number of adult candidates listed, including those registered at multiple centers, rose slightly to 143,982 in 2024 (from 141,865 in 2023) and approached the prepandemic peak of 144,058 in 2019 (Figure KI 2). In 2024, there were 3,743 candidates removed from the waiting list due to death, a decline from 4,734 in 2022 when pandemic effects were still evident, while removals for candidates deemed too sick for transplant increased to 4,901 in 2024, up slightly from 4,855 in 2023; removals also rose for reasons other than death, transplant, improvement, or deterioration (Table KI 5). The demographic profile of the waiting list in 2024 remained stable compared with 2023, with the majority of candidates aged 50 years or older, including 42.1% aged 50-64 years and 26.8% aged 65 years or older, compared with 7.8% aged 18-34 years (Figure KI 3). Unchanged from the previous year, male candidates represented 62.1% of the kidney transplant waiting list in 2024 (Figure KI 4). Since 2013, modest increases have been observed in the proportions of Asian, Hispanic, and Multiracial candidates, while the proportion of White candidates declined to 36.5% in 2024, from 39.8% in 2013 (Figure KI 5). The distribution of primary kidney failure diagnoses in 2024 was similar to that in the prior year, with diabetes continuing its upward trend to 39.1%, hypertension stable at 20.1%, and other/unknown causes increasing slightly to 18.9% (Figure KI 6).

In 2024, the proportion of adult candidates on the kidney transplant waiting list with a waiting time of less than 1 year increased to 39.5%, up from 37.9% in 2023 and substantially higher than 30.4% in 2013. Conversely, the proportion of candidates who, at some point during 2024, had been waiting for 5 years or longer continued its gradual decline, reaching 10.7%, a trend observed since 2018 (Figure KI 7). The percentage of candidates on the waiting list before initiating dialysis showed a continued and encouraging rise to 28.9% in 2024, although 14.3% of adult candidates had been on dialysis for 6 years or more (Figure KI 9). The proportion of candidates with a high body mass index (BMI) also increased slightly in 2024, with 19.5% having a BMI of 35 kg/m² or greater, while 27.4% had a BMI of 30-<35 kg/m² (Figure KI 8). The distribution of candidates by blood type was largely unchanged, with 53.0% having blood type O (Figure KI 10). In addition, the proportion of candidates with a previous kidney transplant declined slightly to 10.5% in 2024, from 10.8% in 2023, continuing a downward trend from 14.4% in 2013 (Figure KI 11). In 2024, 42.0% of candidates were temporarily inactive at waitlist removal or the end of the year, a proportion comparable to 41.8% in 2023 and higher than the 37.7% reported in 2013 (Figure KI 12).

In 2024, the proportion of adult candidates willing to accept a kidney with a high kidney donor profile index (KDPI) score (greater than 85%) remained stable across all age groups, marking the end of a decline observed since the implementation of the revised kidney allocation system (KAS) in December 2014 (Figure KI 13). Such willingness was higher among older candidates, although it was only expressed by 47.8% of those aged 50-64 years and 63.7% of those aged 65 years or older in 2024. In contrast, willingness to accept kidneys from donors who are hepatitis C virus (HCV) antibody positive continued to rise, reaching a majority (56.0%) of adult candidates in 2024 (Figure KI 14). This upward trend follows the availability of highly effective direct-acting antiviral therapies and increasing clinical experience in managing anticipated donor-derived infections with these regimens.

In 2024, DDKT rates among adult waitlisted candidates remained stable compared with 2023, sustaining the recovery from a low point in 2014 (Figure KI 15). Rates declined among candidates aged 18-34 years to 24.1 transplants per 100 patient-years, while those among candidates aged 65 years and older continued to rise, to 24.6—making this age group the most likely to receive DDKT for the first time since 2014. Candidates aged 35-49 years and 50-64 years had slight declines in DDKT rates, to 22.0 and 20.9 transplants per 100 patient-years, respectively (Figure KI 16). Across racial and ethnic groups, DDKT rates were generally stable compared to 2023, with Black candidates having the highest rate at 26.5 transplants per 100 patient-years, reflecting the Organ Procurement and Transplantation Network’s allocation policy changes implemented in January 2023 that grant waiting time credit based on estimated glomerular filtration rate (eGFR) (Figure KI 17).¹ The DDKT rates also remained steady in 2024 across primary kidney failure diagnoses compared to 2023, with the highest observed in candidates with hypertension (25.5 transplants per 100 patient-years) and the lowest in those with diabetes (20.0) (Figure KI 18). Stability was also seen across all cPRA categories compared to 2023; the highest rate occurred in those with cPRA values of 80-<98%, at 33.7 transplants per 100 patient-years, a slight decline from 2023 following a large increase from 2020 to 2021, while the lowest was 18.6 in those with cPRA of 1-<20% (Figure KI 19). The large increase coincided with the implementation of the KAS250 policy in March 2021, as others have noted.²^,³ By blood type, DDKT rates in 2024 remained consistent compared with 2023, at 43.7 transplants per 100 patient-years for blood type AB compared to 19.4 for blood type O (Figure KI 20). The DDKT rates rose among candidates with waiting times of less than 1 year, reaching 29.4 transplants per 100 patient-years, but declined to 17.0 for those waiting 5 or more years (Figure KI 21). The DDKT rates in 2024 also remained slightly higher in female candidates than in male candidates, a pattern observed since 2016 (Figure KI 22).

Transplant within fixed assessment points from listing has increased steadily in recent years. For those listed in 2023, 13.2% of candidates underwent DDKT within 3 months of listing, representing a 251% increase from the 3.8% observed for those listed in 2013. Similarly, the proportion of candidates listed in 2023 who underwent transplant within 6 months rose to 18.3%, a 212% increase from 5.9% for those listed in 2013. Within 1 year of listing, 24.4% of candidates listed in 2023 received a transplant, compared with 8.7% for those listed in 2013 (Figure KI 23). For patients added to the waiting list in 2019-2021, 28.2% were still waiting 3 years after listing, 32.4% had undergone DDKT, 12.9% had undergone LDKT, 6.7% had died, and 19.8% had been removed from the waiting list (Figure KI 24). (Note that in deceased donor kidney allocation, match-run priority is primarily based on candidate duration of organ failure, which can include both time on the list and time on dialysis prior to listing. OPTN policy refers to this duration as “waiting time”; in the Annual Data Report, “waiting time” refers only to time since listing.)

Following the increase in death rates during the COVID-19 pandemic, pretransplant mortality rates declined in 2024 to 4.7 deaths per 100 patient-years, down from 6.2 in 2021 (Figure KI 25), with decreases or stability across race and ethnicity (Figure KI 27), decreases in both male and female candidates (Figure KI 28), and decreases across all blood types (Figure KI 30). By age, the mortality rate in 2024 was lowest among candidates aged 18-34 years and rates declined compared with 2023 across all age groups except for those aged 35-49 years, for whom mortality was stable (Figure KI 26). Declines were also observed across all diagnosis groups in 2024; individuals diagnosed with glomerulonephritis or cystic kidney disease continued to have the lowest mortality rates (Figure KI 29). Pretransplant mortality continued to vary markedly by donation service area, ranging from 2.5 to 7.0 deaths per 100 patient-years (Figure KI 31).

Death within 6 months of removal from the waiting list for reasons other than transplant declined in 2024 from its peak in 2020 (Figure KI 32), with decreases observed across sex (Figure KI 36) and decreases or stability across age groups (Figure KI 34). By diagnosis group, mortality after waitlist removal declined slightly in 2024 compared to 2023 for candidates with diabetes, hypertension, and other/unknown causes of kidney failure; increased slightly among those with cystic kidney disease; and remained stable for those with glomerulonephritis (Figure KI 33). By race, mortality after waitlist removal increased for Multiracial candidates and rose slightly for White candidates but declined among Asian, Black, Hispanic, and Native American candidates in 2024 compared with 2023 (Figure KI 35).

2.2 Transplants

The steady rise in total adult kidney transplants was slowed by the COVID-19 pandemic in 2020 but resumed thereafter. There were a record 27,660 adult kidney transplants in 2024, albeit with only modest growth from 27,351 in 2023 (Figure KI 38). Compared with 2023, the number of DDKTs increased by only 170 and the number of LDKTs increased by 139 (Figure KI 39). In 2024, the proportion of adult DDKTs from donors with KDPI of less than 20% decreased to 20.2%, while most DDKTs were from KDPI 35-<85% donors (52.4%). The proportion of DDKTs from donors with KDPI of 85% or greater rose to 9.5% in 2024, from 6.8% in 2023 (Figure KI 46). By recipient age, transplant counts in 2024 increased most among those aged 65 years or older and declined slightly among those aged 18-34 years (Figure KI 40). Kidney transplant counts increased among Black, Hispanic, Asian, and Multiracial recipients, declined slightly among Native American recipients, and remained stable among White recipients; there were 121 recipients with this information unreported (Figure KI 42). Growth in the number of kidney transplants was similar in the female and male populations (Figure KI 41) and was observed across most diagnosis groups, particularly in patients with hypertension, while declining in those with glomerulonephritis (Figure KI 43). In 2024, growth in kidney transplant occurred in patients without prior kidney transplant, whereas retransplant counts declined slightly (Figure KI 44). First-time recipients accounted for 90.4% of DDKTs and 90.8% of LDKTs in 2024 (Table KI 8).

Disparities in access to LDKT continued in 2024. While 30.5% of adult waitlisted candidates as of December 31, 2024, were Black (Table KI 1), Black patients made up only 13.0% of LDKT recipients, versus 36.4% of DDKT recipients in 2024 (Table KI 6). White patients constituted 35.1% of the waiting list in 2024 (Table KI 1) and accounted for 33.5% of DDKT recipients and 59.9% of LDKT recipients (Table KI 6). Most LDKT recipients (54.8%) had private insurance at the time of transplant in 2024, compared with 27.7% of DDKT recipients (Table KI 6); 61.2% of DDKT recipients were Medicare beneficiaries compared with 37.3% of LDKT recipients (Table KI 6). The tendency for LDKT recipients to have less dialysis time and lower cPRA levels than DDKT recipients continued (Table KI 7). In 2024, 31.8% of LDKT recipients underwent transplant without having received dialysis, compared with 15.0% of DDKT recipients (Table KI 7).

The proportion of adult DDKT recipients with peak cPRA levels of 98-100% increased sharply following the 2014 KAS revision, then gradually declined from 12.5% in 2015 to 6.1% in 2022, followed by slight increases to 7.1% in 2024 (Figure KI 50). After the KAS250 revision in March 2021, the proportion of DDKT recipients with cPRA levels of 80-<98% rose from 7.0% in 2020 to 10.4% in 2021, then declined slightly to 9.7% in 2024 (Figure KI 50). In comparison, only 1.1% of adult LDKT recipients in 2024 had peak cPRA levels of 98-100%, with most (63.6%) having peak cPRA levels of less than 1% (Figure KI 51). Among adult paired LDKT recipients, sensitization was more common than in the overall LDKT population, with 2.2% having cPRA levels of 98-100% and 7.1% having levels of 80-<98% (Figure KI 52). For transplants in 2020-2024, by donor type, 23.7% of DDKTs and 41.8% of LDKTs were performed with three or fewer HLA mismatches, while less than 5% in each group had zero mismatches (Figure KI 53).

Induction immunosuppression was used in 94.3% of kidney transplants in 2024, reflecting a continued increase in proportion since 2013 (Figure KI 47). This trend was driven by the growing use of T-cell–depleting induction agents alone, accounting in 2024 for 76.8% of recipients, while 16.0% received interleukin-2 receptor antibodies (IL2Ab) alone, and 1.5% were reported as receiving both agents (Figure KI 48). Most patients received tacrolimus and mycophenolate-based regimens during the initial transplant hospitalization period, with use of triple therapy including steroids and use of tacrolimus-mycophenolate (without reported steroid use) in 70.4% and 23.0% of recipients, respectively (Figure KI 49).

In 2024, a total of 230 transplant centers performed at least one adult or pediatric kidney transplant (Figure KI 54). The number of high-volume centers (those performing more than 100 transplants annually) increased by 80.7% over roughly the past decade, from 57 in 2013 to 103 in 2024. The number of centers performing 76-100 transplants remained relatively stable during that period, while the number of lower-volume centers declined, including a 29.7% decrease from 64 centers performing 0-25 transplants in 2013 to 45 centers in this volume category in 2024 (Figure KI 55).

2.3 Outcomes

Delayed graft function, defined as dialysis within the first 7 days posttransplant, has trended upward over the past decade but appeared to plateau by 2022; it remained stable at 26.7% overall in 2024 (Figure KI 56). At 12 months, eGFR calculated using the 2021 race-free Chronic Kidney Disease–Epidemiology Collaboration creatinine-based equation as an early surrogate of allograft outcome was 45 mL/min/1.73 m² or higher for 63.1% of adult DDKT recipients in 2023, a slight decline from a high of 67.8% in 2016 (Figure KI 79). Among LDKT recipients in 2023, 78.4% had a 12-month eGFR of 45 mL/min/1.73 m² or higher, down from 82.6% in 2016 (Figure KI 80). For transplants performed in 2023, acute rejection by 1 year was highest in recipients aged 18-34 years (7.4%) and lowest in those aged 50 years or older (5.4%) (Figure KI 81). Rejection at 1 year occurred in 6.7% of recipients who received IL2Ab induction alone, 5.9% in those with T-cell–depleting induction alone, 11.5% in the small subgroup who received both (likely reflecting regimen changes due to early complications), and 4.9% in the small group managed without induction (Figure KI 82). Posttransplant lymphoproliferative disorder remained uncommon and was reported at 5 years in 2.2% of Epstein-Barr virus (EBV)–negative and 0.5% of EBV-positive adult kidney transplant recipients (Figure KI 83).

Among adult DDKT recipients in 2017-2019, 5-year graft survival (where graft loss includes deaths with function) was lowest in older recipients, at 66.1% for those aged 65 years or older compared with 82.5% for those aged 18-34 years (Figure KI 58). Compared with White recipients, 5-year DDKT graft survival was higher among Asian, Hispanic, and Multiracial recipients, but lower among Black and Native American recipients (Figure KI 59). Graft survival was also lower among male compared with female recipients (Figure KI 60) and among recipients with diabetes as the cause of kidney failure compared with other causes (Figure KI 61). Graft survival declined progressively with higher BMI levels (Figure KI 65). Five-year graft survival was 63.6% for allografts with a KDPI of 85% or greater, compared with 85.1%, 80.6%, and 74.3% for KDPI less than 20%, KDPI 20-<35%, and KDPI 35-<85%, respectively (Figure KI 62). Graft survival was only slightly lower for donation after circulatory death (DCD) kidneys compared with donation after brain death (DBD) kidneys (75.2% versus 77.0%; Figure KI 63). Graft survival was lower for kidneys that underwent a procurement biopsy compared to those transplanted without biopsy (72.5% versus 80.8%; Figure KI 64). However, given the high nonuse rate of biopsied kidneys (Figure KI 101) and the uncertain predictive value of biopsy beyond clinical factors, the role of procurement biopsy in guiding organ use remains a topic in need of ongoing study.

Among adult LDKT recipients in 2017-2019, 5-year graft survival was 79.8% in those aged 65 years or older compared with 89.9% in those aged 18-34 years (Figure KI 66). Compared with White recipients, LDKT graft survival was higher among Asian and Hispanic recipients and lower among Black, Multiracial, and Native American recipients (Figure KI 67). Five-year LDKT graft survival was slightly higher among female recipients than male recipients (Figure KI 68). LDKT recipients with diabetic kidney failure had the lowest 5-year graft survival (82.1%), while the highest survival was observed among those with cystic kidney disease (92.6%) and glomerulonephritis (90.3%) (Figure KI 69).

Trends in adult posttransplant patient survival (including deaths with and without graft function) for transplants in 2017-2019 generally mirrored those observed for kidney graft survival. Five years after transplant, patient survival among patients aged 65 years or older was 69.8% for DDKT recipients and 81.6% for LDKT recipients, compared with 95.5% and 98.1%, respectively, for DDKT and LDKT recipients aged 18-34 years (Figure KI 70 and Figure KI 76). Patient survival after DDKT was higher in female recipients than male recipients (Figure KI 72). Compared with White recipients, 5-year patient survival after DDKT was higher among Asian, Black, Hispanic, and Multiracial recipients but lower among Native American recipients (Figure KI 71). A similar pattern was observed among LDKT recipients, except that patient survival among Multiracial and Black recipients was equivalent to that of White recipients (Figure KI 78). Across all racial and ethnic groups, patient survival was higher after LDKT compared with DDKT (Figure KI 71 and Figure KI 78). Five-year patient survival was lowest among recipients with diabetes as the cause of kidney failure: 76.2% for DDKT and 84.8% for LDKT recipients (Figure KI 73 and Figure KI 77). Among DDKT recipients, patient survival declined progressively with increasing donor KDPI, from 91.3% for KDPI of less than 20% to 71.0% for KDPI of 85% or greater (Figure KI 74). Patient survival was also lower for recipients of kidneys that underwent procurement biopsy compared with those of kidneys transplanted without biopsy (Figure KI 75).

3 Donation

3.1 Deceased Donation

The number of deceased donors from whom at least one kidney was recovered for transplant continued to rise in 2024, reaching a record 15,937; however, the increase of 467 donors from the prior year was smaller than the annual growth trend observed since 2019 (Figure KI 84). Deceased donors were most commonly aged 50-64 years, the group with the largest increase compared with 2023 (Figure KI 85). The count of deceased donors aged 65 years or older also increased in 2024, while counts declined among those aged 0-5 years, 18-35 years, and 36-49 years (Figure KI 85). The proportion of deceased donors aged 35 years or younger decreased to 26.5% in 2024, from 31.1% in 2023, whereas the proportion aged 50 years or older was 47.1% in 2024, up from 41.0% (Figure KI 87). The racial and ethnic distribution of deceased kidney donors remained largely unchanged over the past decade, with 67.0% White donors and 14.0% Black donors in 2024 (Figure KI 89). The predominance of male donors (61.3% in 2024) has remained stable since 2013 (Figure KI 88). The counts of HCV antibody–positive deceased donors from whom kidneys were recovered declined slightly in 2024 (Figure KI 86), following a trend of increase from 2013 to 2023. In terms of antibody (Ab) or nucleic acid test (NAT) HCV determination, in 2024, 4.1% of deceased kidney donors were HCV NAT+, down from a peak of 6.6% in 2020, while 4.8% were HCV Ab+/NAT- (Figure KI 90). The proportion of DCD donors continued to increase, reaching 43.8% in 2024 (Figure KI 91). Anoxia remained the leading cause of donor death at 47.9% in 2024, reflecting the ongoing impact of the opioid epidemic; however, the proportion of donors with anoxia as a cause of death decreased slightly from 2023 (49.4%), which may be an early indication that public health successes in the opioid epidemic may change the characteristics of deceased donors available for organ transplant (Figure KI 92).

In 2024, the proportion of deceased donor kidneys recovered for transplant but not transplanted (nonuse rate) rose to a notable high of 29.3%, compared to 18.2% in 2013 (Figure KI 93), with substantial variation by donor characteristics. Nonuse was highest among kidneys recovered from donors aged 65 years or older, at 68.9% (Figure KI 94), and was elevated for kidneys from donors with diabetes, hypertension, or elevated BMI, showing a graded increase for BMI above 25 kg/m², compared to nonuse of kidneys donors without these characteristics (Figure KI 95, Figure KI 98, and Figure KI 99). In 2024, nonuse was highest for kidneys from Black (30.7%) and White (30.3%) donors, and lower for those from Asian donors, Hispanic donors, and donors in the Other category (Figure KI 97). Kidneys evaluated with a procurement biopsy continued to have high nonuse rates, at 40.8% in 2024, compared with 6.4% for nonbiopsied kidneys (Figure KI 101). Similarly, nonuse was 44.1% for kidneys from donors with serum creatinine levels of 1.5 mg/dL or greater, compared to 22.9% for kidneys from donors with lower creatinine levels (Figure KI 100).

In 2024, the nonuse rates for kidneys recovered from HCV Ab+/NAT- and HCV NAT+ donors were 32.2% and 31.0%, respectively, down from 49.5% and 40.2% in 2016 (Figure KI 103), in contrast to the rising nonuse of kidneys from HCV Ab-/NAT- donors. The decrease in nonuse of kidneys from HCV-positive donors is in parallel with broader use of direct-acting antiviral therapy protocols. Kidneys from donors classified as having infection risk factors under the US Public Health Service Guideline were unused less frequently in 2024 than those from donors without risk factors present (22.4% versus 30.6%) (Figure KI 104), likely reflecting their frequent origin from younger donors of otherwise high quality with low KDPI scores. The nonuse rate for kidneys with KDPI of 85% or greater was 69.5% in 2024, a proportion stable since 2022 (Figure KI 106). The impact of KDPI revisions in October 2024 removing race and HCV status will be assessed in future years. In 2024, the nonuse rate for kidneys from DCD donors rose to 36.4% (Figure KI 105). In terms of donor cause of death, nonuse was highest for kidneys from donors who died of cerebrovascular accident/stroke (40.2%), while compared to 2023, only the proportion from donors with anoxia increased, to a nonuse rate of 28.8% (Figure KI 102).

3.2 Living Donation

Following a peak of 6,867 LDKTs in 2019, the number declined to 5,234 in 2020 during the COVID-19 pandemic, then trended upward to 6,419 in 2024 (Figure KI 107). In 2024, among LDKTs performed, directed donations, donations from distantly related (defined as a biological relation other than a parent, child, half sibling, or full sibling) and spousal/partner donors declined compared with 2023, related donor counts remained stable, while paired kidney donations and other living donations increased; notably, 23.4% of LDKTs were performed through donor exchanges (Figure KI 108). As noted above, only a small proportion of waitlisted patients receive an LDKT each year, despite ongoing initiatives to reduce financial barriers to living donation and promote early LDKT.

The age distribution of living kidney donors in 2024 was generally stable compared with 2023, with a slight increase in the proportion aged 40 years or older, while the proportion of young adult donors (aged 18-29 years) reached a low of 11.7% (Figure KI 109). Living donors aged 40-54 years continued to represent the most common age group (Figure KI 109). In 2024, the proportion of female living kidney donors remained consistently high at 64.9% (Figure KI 110). The racial and ethnic composition of living donors was relatively unchanged from 2023, at 67.4% White, 16.3% Hispanic, 8.0% Black, and 5.2% Asian donors (Figure KI 111). The proportion of living donors with a BMI of 30 kg/m² or higher was stable compared to 2023 at 24.1%, including 2.3% with a BMI of 35 kg/m² or higher (Figure KI 113). Most donation surgeries were initiated as laparoscopic hand-assisted (57.0%) or pure laparoscopic procedures (41.8%) (Figure KI 112).

Currently, national data collection for living donation in the United States is limited to those who donate, although the collection of data on living donor candidates, as explored in the SRTR Living Donor Collective (see that chapter in the 2020 Annual Data Report), may provide information on barriers to becoming a living donor as well as controls for postdonation outcomes.⁴

4 Pediatric Kidney Transplant

4.1 Waiting List

In 2024, there were 1,232 pediatric candidates added to the kidney transplant waiting list—a new high (Figure KI 114). The number of prevalent pediatric candidates (listed before age 18 years) had a 37.4% increase over the past decade: 3,109 candidates in 2024 compared with 2,262 in 2013 (Figure KI 115). By age, candidates aged 12 years or older accounted for the largest proportion of those waiting (67.6%), compared with those aged 6-11 years (17.9%), aged 0-5 years (14.5%), and aged 18+ years who were listed before age 18 (30.0%) (Figure KI 116). In terms of race and ethnicity, White candidates made up the largest group (41.7%) on the pediatric kidney transplant waiting list, followed by Hispanic (27.5%), Black (18.8%), Asian (6.0%), Multiracial (3.2%), and Native American (1.0%) candidates; those with this information unreported accounted for 1.9% (Figure KI 117). The proportion of Black candidates has decreased since 2014 (Figure KI 117 and Table KI 11). The distributions by age, sex, and geographic distance to transplant center have remained largely unchanged in that period (Table KI 11). The proportion of candidates with congenital anomalies of the kidney and urinary tract as the primary diagnosis has been stable, while the proportions with glomerulonephritis and focal segmental glomerulosclerosis have decreased and the proportion with other/unknown diagnoses has increased (Table KI 12). Most pediatric candidates waiting as of December 31, 2024, had a cPRA value of less than 1% (64.7%), and the proportion of candidates with cPRA of 80% or greater decreased to 10.7%, from 19.3% in 2014 (Table KI 12). The proportion of pediatric candidates waiting for retransplant declined over the past decade, to 17.3% in 2024 from 27.0% in 2014 (Table KI 13).

The distribution of waiting time among pediatric candidates on the kidney transplant waiting list (active and inactive) has remained stable since 2013, with nearly 50% of candidates waiting for less than 1 year in 2024 (Figure KI 120). Most pediatric candidates on the waiting list in 2024 had a cPRA of less than 1% (64.0%), while the remainder were as follows: 10.8% (cPRA 1-<20%), 15.6% (cPRA 20-<80%), 4.4% (cPRA 80-<98%), and 5.1% (cPRA 98-100%) (Figure KI 121). There has been a steady increase in the proportion of pediatric candidates on the waiting list who were not on dialysis, to 54.7% in 2024 from 32.1% in 2013 (Figure KI 123).

Of the 1,151 pediatric candidates removed from the waiting list in 2024, 703 (61.1%) received a deceased donor kidney, 257 (22.3%) received a living donor kidney, 21 (1.8%) died, 13 (1.1%) were considered too sick to undergo transplant, and 12 (1.0%) were removed from the list because their condition improved. In addition, 2 (0.2%) candidates refused transplant and 142 (12.3%) were removed for Other reasons (Table KI 14 and Table KI 15). For patients newly listed in 2019-2021, within 3 years, 52.5% underwent DDKT, 22.6% underwent LDKT, 15.7% were still waiting, 1.3% died, and 7.9% were removed from the list otherwise (Figure KI 129).

In 2024, the DDKT rate among pediatric waitlist candidates remained stable compared to 2023 at 36.3 transplants per 100 patient-years (Figure KI 124). In 2024, DDKT rates were relatively similar for most pediatric age groups: 42.6, 41.5, and 48.4 transplants per 100 patient-years for age 0-5 years, age 6-11 years, and age 12-17 years, respectively; the rate was 13.5 for candidates who had turned age 18 by the start of the year (Figure KI 125). By race and ethnicity, the highest DDKT rates were among Black (51.4 transplants per 100 patient-years), Other (includes Multiracial, Native American, and unreported; 47.9), and Hispanic candidates (34.6), followed by Asian (30.5) and White candidates (30.0) (Figure KI 126). By cPRA categories, DDKT rates continued to shift, with the highest rate in 2024 among candidates with cPRA of 20-<80% (41.1 transplants per 100 patient-years), followed by those with cPRA of 1-<20% (39.3), cPRA of less than 1% (36.8), cPRA of 98-100% (25.3), and cPRA of 80-<98% (17.9) (Figure KI 127). DDKT rates varied by blood type; in 2024, the rate was 43.5 transplants per 100 patient-years among candidates with type AB, followed by 38.2, 34.1, and 33.1 among candidates with type O, type A, and type B, respectively (Figure KI 128). In 2024, the overall pretransplant mortality rate was 1.2 deaths per 100 patient-years (Figure KI 130). By age, the pretransplant mortality rate was highest among those aged 0-5 years, at 2.8 deaths per 100 patient-years (Figure KI 131); by cPRA, it was highest for those with the most immunologic sensitivity (cPRA 98-100%), at 2.0 (Figure KI 134).

4.2 Transplants

The total number of pediatric kidney transplants performed increased to its highest point—832 transplants in 2024 (Figure KI 135); 601 (72.2%) were DDKTs and 231 (27.8%) were LDKTs (Figure KI 136). This increase was driven by growth in pediatric DDKT; the annual number of pediatric LDKTs has been steady since 2013 (Figure KI 136). The distribution of the relationship of the living donor to the recipient has changed over time. Of note, the number of related living donors had a 23.8% decrease to 131 transplants in 2024 (from 172 in 2013), and the paired donation category remained very low but had a 123.1% increase to 29 transplants in 2024 (from 13 in 2013) (Figure KI 140). Over roughly the past decade, there has been a shift in the distribution of distance between donor hospital and transplant center, with a 33.5% decrease in the proportion of donors who were less than 50 miles from the center: 354 such transplants in 2024 versus 532 in 2013 (Figure KI 141). Children aged 12-17 years were the highest proportion of pediatric LDKT (46.8%), followed by those aged 0-5 years (31.2%) and 6-11 years (22.1%) (Figure KI 144). Regarding donor age, 56.7% of pediatric transplant recipients received a kidney from a donor aged 18-35 years, followed by a kidney from a donor aged 36-49 years (24.4%), a donor aged 12-17 years (13.3%), a donor aged 6-11 years (3.0%), a donor aged 50-64 years (1.8%), and a donor aged 0-5 years (0.7%) (Figure KI 139). In 2024, 25.3% of pediatric DDKTs were preemptive (transplant before starting dialysis) (Figure KI 142). An increasing proportion of pediatric DDKT recipients (80.2%) underwent transplant with a kidney from a donor with KDPI of less than 20%, with an additional 17.6% receiving a kidney from a donor with KDPI of 20-<35% (Figure KI 143).

In 2024, there were 33 programs performing only pediatric kidney transplants (defined as most transplant recipients aged 0-17 years and a small number of adults up to age 21 years), 135 performing only adult transplants (18 years or older), 54 performing mixed transplants (in both adults and children of any age), and 8 functionally adult programs (performing 80% or more transplants in adults and the remainder in adolescents aged 15-17 years) (Figure KI 145). Regarding transplant center volume, 14.8% of kidney transplants in recipients younger than 18 years were performed at programs with a volume of five or fewer pediatric transplants in 2024 (Figure KI 146). Over half (56.1%) of all pediatric recipients who underwent kidney transplant in 2024 were aged 12-17 years: 59.7% of pediatric DDKT recipients and 46.8% of pediatric LDKT recipients (Table KI 16). The racial and ethnic distributions were notably different for DDKT and LDKT recipients. Among LDKT recipients, 66.7% were White, 15.6% were Hispanic, 6.9% were Asian, 5.6% were Black, 2.6% were Multiracial, and 0.4% were Native American; 2.2% had this information unreported. In contrast, among DDKT recipients, 33.3% were White, 27.3% were Hispanic, 26.8% were Black, 5.2% were Asian, 3.2% were Multiracial, and 1.7% were Native American; 2.7% had this information unreported. Private insurance was more common among LDKT recipients (54.1%), and Medicare or Medicaid was more common among DDKT recipients (64.7%) (Table KI 16). Most DDKT recipients (80.5%) had four or more HLA mismatches compared with only 31.4% of LDKT recipients (Figure KI 150). Multiorgan transplant remained uncommon; 3.0% of pediatric candidates received multiorgan kidney transplant in 2024, with kidney-liver transplant being the most common (Table KI 18).

The combination of a donor who was positive for cytomegalovirus and a pediatric recipient who was negative occurred in 37.0% of DDKTs and 34.4% of LDKTs in 2022-2024 (Table KI 19 and Table KI 20). The combination of a donor who was positive for EBV and a pediatric recipient who was negative occurred in 37.9% of DDKTs and 56.3% of LDKTs (Table KI 19 and Table KI 20).

4.3 Immunosuppressive Medication Use

As in the prior years, the majority (90.1%) of pediatric kidney transplant recipients had some induction use reported in 2024 (Figure KI 147). The type of induction agent reported for pediatric recipients was 68.3% T-cell–depleting agent use only, 19.0% IL2Ab use only, and 2.9% a combination of IL2Ab and T-cell–depleting agent use (Figure KI 148). The most common immunosuppression regimens prescribed during the initial transplant hospitalization period were tacrolimus, a mycophenolate agent, and steroids, in 58.1% of recipients, followed by tacrolimus and mycophenolate, in 34.0% (Figure KI 149).

4.4 Outcomes

The rate of delayed graft function was 7.7% for pediatric DDKT recipients and 3.0% for pediatric LDKT recipients in 2024, both stable over the past decade (Figure KI 151 and Figure KI 152). Short-term kidney function, measured by eGFR, has also remained stable during this time frame. Proportions of DDKT and LDKT recipients from 2023 with eGFR of 60 mL/min/1.73 m² or higher at 12 months posttransplant were 70.2% and 70.1%, respectively (Figure KI 167 and Figure KI 168). Graft failure after DDKT in pediatric recipients was 2.4% at 6 months and 3.1% at 1 year for transplants in 2023, 8.0% at 3 years for transplants in 2021, 13.0% at 5 years for transplants in 2019, and 35.2% at 10 years for transplants in 2014 (Figure KI 153). Corresponding graft failure after LDKT was 1.2% at 6 months and 1.7% at 1 year for transplants in 2023, 6.4% at 3 years for transplants in 2021, 6.6% at 5 years for transplants in 2019, and 17.6% at 10 years for transplants in 2014 (Figure KI 154).

For the cohort of pediatric recipients who underwent kidney transplant in 2017-2019, the 1-, 3-, and 5-year graft survival were 97.2%, 93.5%, and 87.3%, respectively, for DDKT recipients and 98.7%, 96.0%, and 92.8%, respectively, for LDKT recipients (Figure KI 156). Graft survival varied by recipient age; the highest 5-year graft survival among pediatric DDKT recipients was in those aged 6-11 years (93.2%) and the lowest was among those aged 12-17 years (83.5%) (Figure KI 157). For graft survival by DDKT recipient diagnosis, 5-year graft survival ranged from 89.9% (congenital anomalies of the kidney and urinary tract) to 85.1% (focal segmental glomerulosclerosis) to 80.1% (glomerulonephritis); it was 87.9% in those with an other/unknown diagnosis (Figure KI 158). For graft survival in DDKT recipients by KDPI, 5-year graft survival was similar for recipients of kidneys with KDPI of 0-<20% (87.3%) and KDPI of 20-<35% (88.1%), with a small decrease among those with KDPI of 35-<85% (83.5%) (Figure KI 159). Graft survival was 100% for the very small number of pediatric DDKT recipients of kidneys with KDPI of 85-100% (Figure KI 143 and Figure KI 159). Graft outcomes also varied by donor age in the 2017-2019 cohort; the 5-year DDKT graft survival was 84.0% for recipients of kidneys from donors aged 0-5 years, 93.7% for kidneys from donors aged 6-11 years, 89.2% kidneys from donors aged 12-17 years, 87.3% for kidneys from donors aged 18-35 years, 83.0% for kidneys from donors aged 36-49 years, and 66.7% for kidneys from donors aged 50-64 years (Figure KI 160).

In the 2023 recipient cohort, the overall incidence of acute rejection within the first year ranged from 9.0% among patients aged 6-11 years and 9.4% among patients aged 12-17 years to 12.8% among patients aged 0-5 years (Figure KI 169). For transplants in 2013-2019, incidence of posttransplant lymphoproliferative disorder among EBV-negative recipients was 4.4% at 5 years posttransplant, compared with 0.9% among EBV-positive recipients (Figure KI 171). Overall, 5-year patient survival among 2017-2019 pediatric DDKT recipients was 97.4% (Figure KI 161), with little variability by recipient age: 96.5% (age 0-5 years), 98.4% (age 6-11 years), and 97.3% (age 12-17 years) (Figure KI 162). Patient survival in this cohort varied little by kidney disease diagnosis (Figure KI 163). Among 2017-2019 pediatric LDKT recipients, 5-year patient survival was 98.7% (Figure KI 164), again with little variability by age (Figure KI 165) and diagnosis (Figure KI 166).

References

Organ Procurement and Transplantation Network. Waiting Time Modifications for Candidates Affected by Race-Inclusive eGFR Calculations. Published online March 12, 2024. Accessed December 9, 2025. https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/waiting-time-modifications-for-candidates-affected-by-race-inclusive-egfr-calculations/

Puttarajappa CM, Hariharan S, Zhang X, Tevar A, Mehta R, Gunabushanam V, Sood P, Hoffman W, Mohan S. Early effect of the circular model of kidney allocation in the United States. J Am Soc Nephrol. 2023;34(1):26-39. doi:10.1681/ASN.2022040471

Andreoni K, Glorioso J, Frank A, Koeneman S, Cocca A, Bodzin A, Maley W, Ramirez C, Shah A. CPRA sensitization priority: The need to recalculate after implementation of 250 nm sharing circles. (Abstract). Am J Transplant. 2025;8(Suppl 1):S19. doi:10.1016/j.ajt.2025.07.027

Fleetwood VA, Lam NN, Lentine KL. Long-term risks of living kidney donation: State of the evidence and strategies to resolve knowledge gaps. Annu Rev Med. 2025;76(1):357-372. doi:10.1146/annurev-med-050223-112648

Support, Copyright, and Citation Information

This publication was produced for the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), by Hennepin Healthcare Research Institute (HHRI) and the United Network for Organ Sharing (UNOS) under contracts HHSH75R60220C00011/HHSH75R60226C00003 and HHSH250201900001C, respectively.

This publication lists nonfederal resources in order to provide additional information to consumers. The views and content in these resources have not been formally approved by HHS or HRSA. Neither HHS nor HRSA endorses the products or services of the listed resources.

The OPTN/SRTR 2024 Annual Data Report is not copyrighted. Readers are free to duplicate and use all or part of the information contained in this publication. Data are not copyrighted and may be used without permission if appropriate citation information is provided.

Pursuant to 42 U.S.C. 1320b-10, this publication may not be reproduced, reprinted, or redistributed for a fee without specific written authorization from HHS.

Suggested Citations:

Full citation: Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2024 Annual Data Report. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2026. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Abbreviated full citation: OPTN/SRTR 2024 Annual Data Report. HHS/HRSA; 2026. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Chapter citation: [Authors]. OPTN/SRTR 2024 Annual Data Report: [chapter]. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Chapter citation for AJT e-supplement available at amjtransplant.org: [Authors]. OPTN/SRTR 2024 Annual Data Report: [chapter]. Am J Transplant. 2026;26([issue and suppl numbers]):[page range]. [doi]

Publications based on data in this report or supplied on request must include a citation and the following statement: The data and analyses reported in the OPTN/SRTR 2024 Annual Data Report have been supplied by the United Network for Organ Sharing and Hennepin Healthcare Research Institute under contract with HHS/HRSA. The authors alone are responsible for reporting and interpreting these data; the views expressed herein are those of the authors and not necessarily those of the U.S. government.

This report is available at https://srtr.transplant.hrsa.gov/annualdatareports. Individual chapters, as well as the report as a whole, may be downloaded.

List of Figures

Figure KI 1: New adult candidates added to the kidney transplant waiting list
Figure KI 2: All adult candidates on the kidney transplant waiting list
Figure KI 3: Distribution of adult candidates waiting for kidney transplant by age
Figure KI 4: Distribution of adult candidates waiting for kidney transplant by sex
Figure KI 5: Distribution of adult candidates waiting for kidney transplant by race and ethnicity
Figure KI 6: Distribution of adult candidates waiting for kidney transplant by diagnosis
Figure KI 7: Distribution of adult candidates waiting for kidney transplant by waiting time
Figure KI 8: Distribution of adult candidates waiting for kidney transplant by BMI
Figure KI 9: Distribution of adult candidates waiting for kidney transplant by years on dialysis
Figure KI 10: Distribution of adult candidates waiting for kidney transplant by blood type
Figure KI 11: Distribution of adult candidates waiting for kidney transplant by prior kidney transplant status
Figure KI 12: Distribution of adult candidates waiting for kidney transplant by active status
Figure KI 13: Adults willing to accept a kidney designated ECD or KDPI > 85% by age
Figure KI 14: Adults willing to accept kidney from HCV Ab+ donor
Figure KI 15: Overall deceased donor kidney transplant rates among adult waitlist candidates
Figure KI 16: Deceased donor kidney transplant rates among adult waitlist candidates by age
Figure KI 17: Deceased donor kidney transplant rates among adult waitlist candidates by race and ethnicity
Figure KI 18: Deceased donor kidney transplant rates among adult waitlist candidates by diagnosis
Figure KI 19: Deceased donor kidney transplant rates among adult waitlist candidates by cPRA
Figure KI 20: Deceased donor kidney transplant rates among adult waitlist candidates by blood type
Figure KI 21: Deceased donor kidney transplant rates among adult waitlist candidates by time on the waiting list
Figure KI 22: Deceased donor kidney transplant rates among adult waitlist candidates by sex
Figure KI 23: Percentages of adults who underwent deceased donor kidney transplant within a given period of listing
Figure KI 24: Three-year outcomes for adults waiting for kidney transplant, new listings in 2019-2021
Figure KI 25: Overall pretransplant mortality rates among adult candidates waitlisted for kidney transplant
Figure KI 26: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by age
Figure KI 27: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by race and ethnicity
Figure KI 28: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by sex
Figure KI 29: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by diagnosis
Figure KI 30: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by blood type
Figure KI 31: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant in 2024 by DSA
Figure KI 32: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates overall
Figure KI 33: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by diagnosis group at removal
Figure KI 34: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by age
Figure KI 35: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by race and ethnicity
Figure KI 36: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by sex
Figure KI 37: Overall kidney transplants
Figure KI 38: Overall adult kidney transplants
Figure KI 39: Adult kidney transplants by donor type
Figure KI 40: Adult kidney transplants by recipient age
Figure KI 41: Adult kidney transplants by sex
Figure KI 42: Adult kidney transplants by race and ethnicity
Figure KI 43: Adult kidney transplants by diagnosis
Figure KI 44: Adult kidney transplants by prior kidney transplant status
Figure KI 45: Adult kidney transplants by distance between donor and center
Figure KI 46: Percentages of adult kidney transplants by KDPI
Figure KI 47: Induction agent use in adult kidney transplant recipients
Figure KI 48: Type of induction agent use in adult kidney transplant recipients
Figure KI 49: Immunosuppression regimen use in adult kidney transplant recipients
Figure KI 50: Peak cPRA at time of kidney transplant in adult deceased donor recipients
Figure KI 51: Peak cPRA at time of kidney transplant in adult living donor recipients
Figure KI 52: Peak cPRA at time of kidney transplant in adult paired living donor recipients
Figure KI 53: Total HLA A, B, and DR mismatches among adult kidney transplant recipients, 2020-2024
Figure KI 54: Number of centers performing at least one pediatric or adult kidney transplant
Figure KI 55: Number of centers performing at least one pediatric or adult kidney transplant by number of transplants performed
Figure KI 56: Delayed graft function among adult kidney transplant recipients
Figure KI 57: Percentages of patient deaths among adult kidney transplant recipients
Figure KI 58: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by age
Figure KI 59: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by race and ethnicity
Figure KI 60: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by sex
Figure KI 61: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by diagnosis
Figure KI 62: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by KDPI
Figure KI 63: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by DBD and DCD status
Figure KI 64: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by biopsy status
Figure KI 65: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by BMI
Figure KI 66: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by age
Figure KI 67: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by race and ethnicity
Figure KI 68: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by sex
Figure KI 69: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by diagnosis
Figure KI 70: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by age
Figure KI 71: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by race and ethnicity
Figure KI 72: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by sex
Figure KI 73: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by diagnosis
Figure KI 74: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by KDPI
Figure KI 75: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by biopsy status
Figure KI 76: Patient survival among adult living donor kidney transplant recipients, 2017-2019, by age
Figure KI 77: Patient survival among adult living donor kidney transplant recipients, 2017-2019, by diagnosis
Figure KI 78: Patient survival among adult living donor kidney transplant recipients, 2017-2019, by race and ethnicity
Figure KI 79: Distribution of eGFR at 12 months posttransplant among adult deceased donor kidney transplant recipients
Figure KI 80: Distribution of eGFR at 12 months posttransplant among adult living donor kidney transplant recipients
Figure KI 81: Incidence of acute rejection by 1 year posttransplant among adult kidney transplant recipients by age
Figure KI 82: Incidence of acute rejection by 1 year posttransplant among adult kidney transplant recipients by induction agent
Figure KI 83: Incidence of PTLD among adult kidney transplant recipients by recipient EBV status at transplant, 2013-2019
Figure KI 84: Overall deceased kidney donor count
Figure KI 85: Deceased kidney donor count by age
Figure KI 86: Deceased kidney donor count by HCV status
Figure KI 87: Distribution of deceased kidney donors by age
Figure KI 88: Distribution of deceased kidney donors by sex
Figure KI 89: Distribution of deceased kidney donors by race and ethnicity
Figure KI 90: Distribution of deceased kidney donors by donor HCV status
Figure KI 91: Distribution of deceased kidney donors by DBD and DCD status
Figure KI 92: Cause of death among deceased kidney donors
Figure KI 93: Overall percentages of kidneys recovered for transplant and not transplanted
Figure KI 94: Percentages of kidneys recovered for transplant and not transplanted by donor age
Figure KI 95: Percentages of kidneys recovered for transplant and not transplanted by donor diabetes status
Figure KI 96: Percentages of kidneys recovered for transplant and not transplanted by donor sex
Figure KI 97: Percentages of kidneys recovered for transplant and not transplanted by donor race and ethnicity
Figure KI 98: Percentages of kidneys recovered for transplant and not transplanted by donor hypertension status
Figure KI 99: Percentages of kidneys recovered for transplant and not transplanted by donor BMI
Figure KI 100: Percentages of kidneys recovered for transplant and not transplanted by donor terminal creatinine
Figure KI 101: Percentages of kidneys recovered for transplant and not transplanted by donor biopsy status
Figure KI 102: Percentages of kidneys recovered for transplant and not transplanted by donor cause of death
Figure KI 103: Percentages of kidneys recovered for transplant and not transplanted by donor HCV status
Figure KI 104: Percentages of kidneys recovered for transplant and not transplanted, by donor risk of disease transmission
Figure KI 105: Percentages of kidneys recovered for transplant and not transplanted by DBD and DCD status
Figure KI 106: Percentages of kidneys recovered for transplant and not transplanted by KDPI
Figure KI 107: Overall number of living kidney donors
Figure KI 108: Number of living kidney donors by donor relation
Figure KI 109: Living kidney donors by age
Figure KI 110: Living kidney donors by sex
Figure KI 111: Living kidney donors by race and ethnicity
Figure KI 112: Living kidney donors by BMI
Figure KI 113: Intended living kidney donor procedure type
Figure KI 114: New pediatric candidates added to the kidney transplant waiting list
Figure KI 115: All pediatric candidates on the kidney transplant waiting list
Figure KI 116: Distribution of pediatric candidates waiting for kidney transplant by age
Figure KI 117: Distribution of pediatric candidates waiting for kidney transplant by race and ethnicity
Figure KI 118: Distribution of pediatric candidates waiting for kidney transplant by diagnosis
Figure KI 119: Distribution of pediatric candidates waiting for kidney transplant by sex
Figure KI 120: Distribution of pediatric candidates waiting for kidney transplant by waiting time
Figure KI 121: Distribution of pediatric candidates waiting for kidney transplant by cPRA
Figure KI 122: Distribution of pediatric candidates waiting for kidney transplant by blood type
Figure KI 123: Distribution of pediatric candidates waiting for kidney transplant by years on dialysis
Figure KI 124: Overall deceased donor kidney transplant rates among pediatric waitlist candidates
Figure KI 125: Deceased donor kidney transplant rates among pediatric waitlist candidates by age
Figure KI 126: Deceased donor kidney transplant rates among pediatric waitlist candidates by race and ethnicity
Figure KI 127: Deceased donor kidney transplant rates among pediatric waitlist candidates by cPRA
Figure KI 128: Deceased donor kidney transplant rates among pediatric waitlist candidates by blood type
Figure KI 129: Three-year outcomes for newly listed pediatric candidates waiting for kidney transplant, 2019-2021
Figure KI 130: Overall pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant
Figure KI 131: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by age
Figure KI 132: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by race and ethnicity
Figure KI 133: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by diagnosis
Figure KI 134: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by cPRA
Figure KI 135: Overall pediatric kidney transplants
Figure KI 136: Pediatric kidney transplants by donor type
Figure KI 137: Pediatric kidney transplants by recipient age
Figure KI 138: Pediatric kidney transplants by diagnosis
Figure KI 139: Pediatric kidney transplants by donor age
Figure KI 140: Number of living donor pediatric kidney transplants by donor relation
Figure KI 141: Pediatric kidney transplants by distance between donor and center
Figure KI 142: Percentages of pediatric deceased donor kidney transplants by years on dialysis
Figure KI 143: Percentages of pediatric deceased donor kidney transplants by KDPI
Figure KI 144: Percentages of pediatric kidney transplants from living donors by recipient age
Figure KI 145: Number of centers performing pediatric and adult kidney transplants by center age mix
Figure KI 146: Percentages of pediatric kidney recipients by age at programs that perform five or fewer pediatric transplants annually
Figure KI 147: Induction agent use in pediatric kidney transplant recipients
Figure KI 148: Type of induction agent use in pediatric kidney transplant recipients
Figure KI 149: Immunosuppression regimen use in pediatric kidney transplant recipients
Figure KI 150: Total HLA A, B, and DR mismatches among pediatric kidney transplant recipients, 2020-2024
Figure KI 151: Delayed graft function among pediatric deceased donor kidney transplant recipients
Figure KI 152: Delayed graft function among pediatric living donor kidney transplant recipients
Figure KI 153: Graft failure among pediatric deceased donor kidney transplant recipients
Figure KI 154: Graft failure among pediatric living donor kidney transplant recipients
Figure KI 155: Percentages of patient deaths among pediatric kidney transplant recipients
Figure KI 156: Graft survival among pediatric kidney transplant recipients, 2017-2019, by donor type
Figure KI 157: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by age
Figure KI 158: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by diagnosis
Figure KI 159: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by KDPI
Figure KI 160: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by donor age
Figure KI 161: Overall patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019
Figure KI 162: Patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by recipient age
Figure KI 163: Patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by diagnosis
Figure KI 164: Overall patient survival among pediatric living donor kidney transplant recipients, 2017-2019
Figure KI 165: Patient survival among pediatric living donor kidney transplant recipients, 2017-2019, by recipient age
Figure KI 166: Patient survival among pediatric living donor kidney transplant recipients, 2017-2019, by diagnosis
Figure KI 167: Distribution of eGFR at 12 months posttransplant among pediatric deceased donor kidney transplant recipients
Figure KI 168: Distribution of eGFR at 12 months posttransplant among pediatric living donor kidney transplant recipients
Figure KI 169: Incidence of acute rejection by 1 year posttransplant among pediatric kidney transplant recipients by age
Figure KI 170: Incidence of acute rejection by 1 year posttransplant among pediatric kidney transplant recipients by induction agent use
Figure KI 171: Incidence of PTLD among pediatric kidney transplant recipients by recipient EBV status at transplant, 2013-2019

List of Tables

Table KI 1: Demographic characteristics of adults on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024
Table KI 2: Clinical characteristics of adults on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024
Table KI 3: Listing characteristics of adults on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024
Table KI 4: Kidney transplant waitlist activity among adults
Table KI 5: Removal reason among adult kidney transplant candidates
Table KI 6: Demographic characteristics of adult kidney transplant recipients, 2024
Table KI 7: Clinical characteristics of adult kidney transplant recipients, 2024
Table KI 8: Transplant characteristics of adult kidney transplant recipients, 2024
Table KI 9: Adult deceased donor kidney donor-recipient serology matching, 2022-2024
Table KI 10: Adult living donor kidney donor-recipient serology matching, 2022-2024
Table KI 11: Demographic characteristics of pediatric candidates on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024
Table KI 12: Clinical characteristics of pediatric candidates on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024
Table KI 13: Listing characteristics of pediatric candidates on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024
Table KI 14: Kidney transplant waitlist activity among pediatric candidates
Table KI 15: Removal reason among pediatric kidney transplant candidates
Table KI 16: Demographic characteristics of pediatric kidney transplant recipients, 2024
Table KI 17: Clinical characteristics of pediatric kidney transplant recipients, 2024
Table KI 18: Transplant characteristics of pediatric kidney transplant recipients, 2024
Table KI 19: Pediatric deceased donor kidney donor-recipient serology matching, 2022-2024
Table KI 20: Pediatric living donor kidney donor-recipient serology matching, 2022-2024

**New adult candidates added to the kidney transplant waiting list.** A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and subsequently relisted are considered new. Active and inactive patients are included. Candidates listed at more than one center are counted once per listing. Includes kidney and kidney-pancreas listings.

Figure KI 1: New adult candidates added to the kidney transplant waiting list. A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and subsequently relisted are considered new. Active and inactive patients are included. Candidates listed at more than one center are counted once per listing. Includes kidney and kidney-pancreas listings.

**All adult candidates on the kidney transplant waiting list.** Adult candidates on the list at any time during the year. Candidates listed at more than one center are counted once per listing. Includes kidney and kidney-pancreas candidates.

Figure KI 2: All adult candidates on the kidney transplant waiting list. Adult candidates on the list at any time during the year. Candidates listed at more than one center are counted once per listing. Includes kidney and kidney-pancreas candidates.

**Distribution of adult candidates waiting for kidney transplant by age.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year.

Figure KI 3: Distribution of adult candidates waiting for kidney transplant by age. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year.

**Distribution of adult candidates waiting for kidney transplant by sex.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 4: Distribution of adult candidates waiting for kidney transplant by sex. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for kidney transplant by race and ethnicity.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 5: Distribution of adult candidates waiting for kidney transplant by race and ethnicity. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for kidney transplant by diagnosis.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 6: Distribution of adult candidates waiting for kidney transplant by diagnosis. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for kidney transplant by waiting time.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Candidates listed in the given year are considered to have been listed less than 1 year. Active and inactive candidates are included.

Figure KI 7: Distribution of adult candidates waiting for kidney transplant by waiting time. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Candidates listed in the given year are considered to have been listed less than 1 year. Active and inactive candidates are included.

**Distribution of adult candidates waiting for kidney transplant by BMI.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. BMI, body mass index.

Figure KI 8: Distribution of adult candidates waiting for kidney transplant by BMI. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. BMI, body mass index.

**Distribution of adult candidates waiting for kidney transplant by years on dialysis.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on dialysis is computed as time from minimum of first end-stage renal disease service date or most recent graft failure to listing date or January 1 of the given year. Active and inactive candidates are included.

Figure KI 9: Distribution of adult candidates waiting for kidney transplant by years on dialysis. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on dialysis is computed as time from minimum of first end-stage renal disease service date or most recent graft failure to listing date or January 1 of the given year. Active and inactive candidates are included.

**Distribution of adult candidates waiting for kidney transplant by blood type.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 10: Distribution of adult candidates waiting for kidney transplant by blood type. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for kidney transplant by prior kidney transplant status.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 11: Distribution of adult candidates waiting for kidney transplant by prior kidney transplant status. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adult candidates waiting for kidney transplant by active status.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. Active status is determined at the earliest of transplant, death, removal, or December 31 of the year.

Figure KI 12: Distribution of adult candidates waiting for kidney transplant by active status. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. Active status is determined at the earliest of transplant, death, removal, or December 31 of the year.

Figure KI 13: Adults willing to accept a kidney designated ECD or KDPI > 85% by age. Adults waiting for kidney transplant on December 31 of the given year. Candidates listed at more than one center are counted once per listing. Willingness to accept ECD kidney at time of listing or willingness to accept a local non-zero HLA mismatch KDPI > 85% kidney at the later of listing date or January 1 of the given year, beginning in 2014. ECD, expanded-criteria donor; KDPI, kidney donor profile index.

**Adults willing to accept kidney from HCV Ab+ donor.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Willingness to accept HCV Ab+ organ at time of listing. Ab, antibody; HCV, hepatitis C virus.

Figure KI 14: Adults willing to accept kidney from HCV Ab+ donor. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Willingness to accept HCV Ab+ organ at time of listing. Ab, antibody; HCV, hepatitis C virus.

**Overall deceased donor kidney transplant rates among adult waitlist candidates.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure KI 15: Overall deceased donor kidney transplant rates among adult waitlist candidates. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor kidney transplant rates among adult waitlist candidates by age.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

Figure KI 16: Deceased donor kidney transplant rates among adult waitlist candidates by age. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

**Deceased donor kidney transplant rates among adult waitlist candidates by race and ethnicity.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 17: Deceased donor kidney transplant rates among adult waitlist candidates by race and ethnicity. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Deceased donor kidney transplant rates among adult waitlist candidates by diagnosis.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure KI 18: Deceased donor kidney transplant rates among adult waitlist candidates by diagnosis. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor kidney transplant rates among adult waitlist candidates by cPRA.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. cPRA is determined at the later of listing date or January 1 of the given year. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure KI 19: Deceased donor kidney transplant rates among adult waitlist candidates by cPRA. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. cPRA is determined at the later of listing date or January 1 of the given year. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**Deceased donor kidney transplant rates among adult waitlist candidates by blood type.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure KI 20: Deceased donor kidney transplant rates among adult waitlist candidates by blood type. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor kidney transplant rates among adult waitlist candidates by time on the waiting list.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure KI 21: Deceased donor kidney transplant rates among adult waitlist candidates by time on the waiting list. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor kidney transplant rates among adult waitlist candidates by sex.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure KI 22: Deceased donor kidney transplant rates among adult waitlist candidates by sex. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Percentages of adults who underwent deceased donor kidney transplant within a given period of listing.** Candidates listed at more than one center are counted once per listing.

Figure KI 23: Percentages of adults who underwent deceased donor kidney transplant within a given period of listing. Candidates listed at more than one center are counted once per listing.

**Three-year outcomes for adults waiting for kidney transplant, new listings in 2019-2021.** Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure KI 24: Three-year outcomes for adults waiting for kidney transplant, new listings in 2019-2021. Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Overall pretransplant mortality rates among adult candidates waitlisted for kidney transplant.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure KI 25: Overall pretransplant mortality rates among adult candidates waitlisted for kidney transplant. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by age.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

Figure KI 26: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by age. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

**Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by race and ethnicity.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 27: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by race and ethnicity. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by sex.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure KI 28: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by sex. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by diagnosis.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure KI 29: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by diagnosis. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by blood type.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure KI 30: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant by blood type. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adult candidates waitlisted for kidney transplant in 2024 by DSA.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. DSA, donation service area.

Figure KI 31: Pretransplant mortality rates among adult candidates waitlisted for kidney transplant in 2024 by DSA. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. DSA, donation service area.

**Percentages of deaths within 6 months after removal among adult kidney waitlist candidates overall.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure KI 32: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates overall. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

**Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by diagnosis group at removal.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure KI 33: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by diagnosis group at removal. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

**Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by age.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list. Age is determined at removal.

Figure KI 34: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by age. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list. Age is determined at removal.

**Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by race and ethnicity.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure KI 35: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by race and ethnicity. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

**Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by sex.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure KI 36: Percentages of deaths within 6 months after removal among adult kidney waitlist candidates by sex. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure KI 37: Overall kidney transplants. All kidney transplants, including adult and pediatric, retransplant, and multiorgan.

Figure KI 38: Overall adult kidney transplants. All adult kidney transplants, including retransplant and multiorgan.

Figure KI 39: Adult kidney transplants by donor type. Adult kidney transplants, including retransplant and multiorgan.

**Adult kidney transplants by recipient age.** Adult kidney transplants, including retransplant and multiorgan. Age is recipient age at transplant.

Figure KI 40: Adult kidney transplants by recipient age. Adult kidney transplants, including retransplant and multiorgan. Age is recipient age at transplant.

Figure KI 41: Adult kidney transplants by sex. Adult kidney transplants, including retransplant and multiorgan.

Figure KI 42: Adult kidney transplants by race and ethnicity. Adult kidney transplants, including retransplant and multiorgan.

Figure KI 43: Adult kidney transplants by diagnosis. Adult kidney transplants, including retransplant and multiorgan.

Figure KI 44: Adult kidney transplants by prior kidney transplant status. Adult kidney transplants, including retransplant and multiorgan.

**Adult kidney transplants by distance between donor and center.** All adult kidney transplants, including retransplant and multiorgan. Distance between donor and center is computed from donor hospital to the transplant center.

Figure KI 45: Adult kidney transplants by distance between donor and center. All adult kidney transplants, including retransplant and multiorgan. Distance between donor and center is computed from donor hospital to the transplant center.

Figure KI 46: Percentages of adult kidney transplants by KDPI. All adult recipients of deceased donor kidneys, including multiorgan transplant recipients. Conversion of kidney donor risk index to KDPI is done using the OPTN KDPI Mapping Tables. For donor organs recovered January through May, the cohort 2 years prior was used to assign KDPI; for donor organs recovered June through December, the cohort 1 year prior was used to assign KDPI. Kidneys recovered en bloc are counted once. KDPI, kidney donor profile index.

**Induction agent use in adult kidney transplant recipients.** All adult kidney transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN.

Figure KI 47: Induction agent use in adult kidney transplant recipients. All adult kidney transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN.

**Type of induction agent use in adult kidney transplant recipients.** All adult kidney transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

Figure KI 48: Type of induction agent use in adult kidney transplant recipients. All adult kidney transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

**Immunosuppression regimen use in adult kidney transplant recipients.** All adult kidney transplants, including retransplant and multiorgan. Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

Figure KI 49: Immunosuppression regimen use in adult kidney transplant recipients. All adult kidney transplants, including retransplant and multiorgan. Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

**Peak cPRA at time of kidney transplant in adult deceased donor recipients.** All adult kidney transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure KI 50: Peak cPRA at time of kidney transplant in adult deceased donor recipients. All adult kidney transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**Peak cPRA at time of kidney transplant in adult living donor recipients.** All adult kidney transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure KI 51: Peak cPRA at time of kidney transplant in adult living donor recipients. All adult kidney transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**Peak cPRA at time of kidney transplant in adult paired living donor recipients.** All adult kidney transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure KI 52: Peak cPRA at time of kidney transplant in adult paired living donor recipients. All adult kidney transplants, including retransplant and multiorgan. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**Total HLA A, B, and DR mismatches among adult kidney transplant recipients, 2020-2024.** All adult kidney transplants, including retransplant and multiorgan. Donor and recipient antigen matching is based on OPTN antigen values and split equivalences policy as of 2024. Unk, unknown.

Figure KI 53: Total HLA A, B, and DR mismatches among adult kidney transplant recipients, 2020-2024. All adult kidney transplants, including retransplant and multiorgan. Donor and recipient antigen matching is based on OPTN antigen values and split equivalences policy as of 2024. Unk, unknown.

**Number of centers performing at least one pediatric or adult kidney transplant.** Count of all centers that have performed at least one kidney transplant.

Figure KI 54: Number of centers performing at least one pediatric or adult kidney transplant. Count of all centers that have performed at least one kidney transplant.

**Number of centers performing at least one pediatric or adult kidney transplant by number of transplants performed.** Count of all centers that have performed at least one kidney transplant.

Figure KI 55: Number of centers performing at least one pediatric or adult kidney transplant by number of transplants performed. Count of all centers that have performed at least one kidney transplant.

**Delayed graft function among adult kidney transplant recipients.** All adult recipients of kidneys. Delayed graft function is defined as dialysis administered within the first 7 days posttransplant. DGF, delayed graft function.

Figure KI 56: Delayed graft function among adult kidney transplant recipients. All adult recipients of kidneys. Delayed graft function is defined as dialysis administered within the first 7 days posttransplant. DGF, delayed graft function.

**Percentages of patient deaths among adult kidney transplant recipients.** All adult recipients of deceased donor kidneys, including multiorgan transplant recipients.

Figure KI 57: Percentages of patient deaths among adult kidney transplant recipients. All adult recipients of deceased donor kidneys, including multiorgan transplant recipients.

**Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by age.** Graft survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

Figure KI 58: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by age. Graft survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

**Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by race and ethnicity.** Graft survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 59: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by race and ethnicity. Graft survival estimated using unadjusted Kaplan-Meier methods.

**Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by sex.** Graft survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 60: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by sex. Graft survival estimated using unadjusted Kaplan-Meier methods.

**Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by diagnosis.** Graft survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 61: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by diagnosis. Graft survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 62: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by KDPI. Graft survival estimated using unadjusted Kaplan-Meier methods. Conversion of kidney donor risk index to KDPI is done using the OPTN KDPI Mapping Tables. For donor organs recovered January through May, the cohort 2 years prior was used to assign KDPI; for donor organs recovered June through December, the cohort 1 year prior was used to assign KDPI. KDPI, kidney donor profile index.

**Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by DBD and DCD status.** Graft survival estimated using unadjusted Kaplan-Meier methods. DBD, donation after brain death; DCD, donation after circulatory death.

Figure KI 63: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by DBD and DCD status. Graft survival estimated using unadjusted Kaplan-Meier methods. DBD, donation after brain death; DCD, donation after circulatory death.

**Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by biopsy status.** Graft survival estimated using unadjusted Kaplan-Meier methods. Kidneys are classified as biopsied if either of the donor's kidneys was biopsied.

Figure KI 64: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by biopsy status. Graft survival estimated using unadjusted Kaplan-Meier methods. Kidneys are classified as biopsied if either of the donor’s kidneys was biopsied.

**Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by BMI.** Graft survival estimated using unadjusted Kaplan-Meier methods. BMI, body mass index.

Figure KI 65: Graft survival among adult deceased donor kidney transplant recipients, 2017-2019, by BMI. Graft survival estimated using unadjusted Kaplan-Meier methods. BMI, body mass index.

**Graft survival among adult living donor kidney transplant recipients, 2017-2019, by age.** Graft survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

Figure KI 66: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by age. Graft survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

**Graft survival among adult living donor kidney transplant recipients, 2017-2019, by race and ethnicity.** Graft survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 67: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by race and ethnicity. Graft survival estimated using unadjusted Kaplan-Meier methods.

**Graft survival among adult living donor kidney transplant recipients, 2017-2019, by sex.** Graft survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 68: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by sex. Graft survival estimated using unadjusted Kaplan-Meier methods.

**Graft survival among adult living donor kidney transplant recipients, 2017-2019, by diagnosis.** Graft survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 69: Graft survival among adult living donor kidney transplant recipients, 2017-2019, by diagnosis. Graft survival estimated using unadjusted Kaplan-Meier methods.

**Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by age.** Patient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

Figure KI 70: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by age. Patient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

**Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by race and ethnicity.** Patient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 71: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by race and ethnicity. Patient survival estimated using unadjusted Kaplan-Meier methods.

**Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by sex.** Patient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 72: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by sex. Patient survival estimated using unadjusted Kaplan-Meier methods.

**Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by diagnosis.** Patient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 73: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by diagnosis. Patient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 74: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by KDPI. Patient survival estimated using unadjusted Kaplan-Meier methods. Conversion of kidney donor risk index to KDPI is done using the OPTN KDPI Mapping Tables. For donor organs recovered January through May, the cohort 2 years prior was used to assign KDPI; for donor organs recovered June through December, the cohort 1 year prior was used to assign KDPI. KDPI, kidney donor profile index.

**Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by biopsy status.** Patient survival estimated using unadjusted Kaplan-Meier methods. Kidneys are classified as biopsied if either of the donor's kidneys was biopsied.

Figure KI 75: Patient survival among adult deceased donor kidney transplant recipients, 2017-2019, by biopsy status. Patient survival estimated using unadjusted Kaplan-Meier methods. Kidneys are classified as biopsied if either of the donor’s kidneys was biopsied.

**Patient survival among adult living donor kidney transplant recipients, 2017-2019, by age.** Patient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

Figure KI 76: Patient survival among adult living donor kidney transplant recipients, 2017-2019, by age. Patient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

**Patient survival among adult living donor kidney transplant recipients, 2017-2019, by diagnosis.** Patient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 77: Patient survival among adult living donor kidney transplant recipients, 2017-2019, by diagnosis. Patient survival estimated using unadjusted Kaplan-Meier methods.

**Patient survival among adult living donor kidney transplant recipients, 2017-2019, by race and ethnicity.** Patient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 78: Patient survival among adult living donor kidney transplant recipients, 2017-2019, by race and ethnicity. Patient survival estimated using unadjusted Kaplan-Meier methods.

**Distribution of eGFR at 12 months posttransplant among adult deceased donor kidney transplant recipients.** Glomerular filtration rate (mL/min/1.73 m^2^) estimated using the race-free 2021 Chronic Kidney Disease--Epidemiology Collaboration equation, and computed by SRTR for patients alive with graft function at 12 months posttransplant. eGFR, estimated glomerular filtration rate.

Figure KI 79: Distribution of eGFR at 12 months posttransplant among adult deceased donor kidney transplant recipients. Glomerular filtration rate (mL/min/1.73 m²) estimated using the race-free 2021 Chronic Kidney Disease–Epidemiology Collaboration equation, and computed by SRTR for patients alive with graft function at 12 months posttransplant. eGFR, estimated glomerular filtration rate.

**Distribution of eGFR at 12 months posttransplant among adult living donor kidney transplant recipients.** Glomerular filtration rate (mL/min/1.73 m^2^) estimated using the race-free 2021 Chronic Kidney Disease--Epidemiology Collaboration equation, and computed by SRTR for patients alive with graft function at 12 months posttransplant. eGFR, estimated glomerular filtration rate.

Figure KI 80: Distribution of eGFR at 12 months posttransplant among adult living donor kidney transplant recipients. Glomerular filtration rate (mL/min/1.73 m²) estimated using the race-free 2021 Chronic Kidney Disease–Epidemiology Collaboration equation, and computed by SRTR for patients alive with graft function at 12 months posttransplant. eGFR, estimated glomerular filtration rate.

**Incidence of acute rejection by 1 year posttransplant among adult kidney transplant recipients by age.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Age is recipient age at transplant.

Figure KI 81: Incidence of acute rejection by 1 year posttransplant among adult kidney transplant recipients by age. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Age is recipient age at transplant.

**Incidence of acute rejection by 1 year posttransplant among adult kidney transplant recipients by induction agent.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

Figure KI 82: Incidence of acute rejection by 1 year posttransplant among adult kidney transplant recipients by induction agent. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

**Incidence of PTLD among adult kidney transplant recipients by recipient EBV status at transplant, 2013-2019.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure KI 83: Incidence of PTLD among adult kidney transplant recipients by recipient EBV status at transplant, 2013-2019. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure KI 84: Overall deceased kidney donor count. Count of deceased donors from whom at least one kidney was recovered for transplant.

Figure KI 85: Deceased kidney donor count by age. Count of deceased donors from whom at least one kidney was recovered for transplant.

**Deceased kidney donor count by HCV status.** Count of deceased donors from whom at least one kidney was recovered for transplant. Donor HCV status was based on an antibody test. HCV, hepatitis C virus.

Figure KI 86: Deceased kidney donor count by HCV status. Count of deceased donors from whom at least one kidney was recovered for transplant. Donor HCV status was based on an antibody test. HCV, hepatitis C virus.

Figure KI 87: Distribution of deceased kidney donors by age. Deceased donors from whom at least one kidney was recovered for transplant.

Figure KI 88: Distribution of deceased kidney donors by sex. Deceased donors from whom at least one kidney was recovered for transplant.

**Distribution of deceased kidney donors by race and ethnicity.** Deceased donors from whom at least one kidney was recovered for transplant. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 89: Distribution of deceased kidney donors by race and ethnicity. Deceased donors from whom at least one kidney was recovered for transplant. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Distribution of deceased kidney donors by donor HCV status.** Deceased donors from whom at least one kidney was recovered for transplant. Donor HCV status was based on NAT and antibody tests. Ab, antibody; HCV, hepatitis C virus; NAT, nucleic acid test.

Figure KI 90: Distribution of deceased kidney donors by donor HCV status. Deceased donors from whom at least one kidney was recovered for transplant. Donor HCV status was based on NAT and antibody tests. Ab, antibody; HCV, hepatitis C virus; NAT, nucleic acid test.

**Distribution of deceased kidney donors by DBD and DCD status.** Deceased donors whose kidneys were recovered for transplant. DBD, donation after brain death; DCD, donation after circulatory death.

Figure KI 91: Distribution of deceased kidney donors by DBD and DCD status. Deceased donors whose kidneys were recovered for transplant. DBD, donation after brain death; DCD, donation after circulatory death.

**Cause of death among deceased kidney donors.** Deceased donors with at least one kidney recovered for transplant. Each donor is counted once. CVA, cerebrovascular accident.

Figure KI 92: Cause of death among deceased kidney donors. Deceased donors with at least one kidney recovered for transplant. Each donor is counted once. CVA, cerebrovascular accident.

**Overall percentages of kidneys recovered for transplant and not transplanted.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

Figure KI 93: Overall percentages of kidneys recovered for transplant and not transplanted. Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

**Percentages of kidneys recovered for transplant and not transplanted by donor age.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

Figure KI 94: Percentages of kidneys recovered for transplant and not transplanted by donor age. Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

**Percentages of kidneys recovered for transplant and not transplanted by donor diabetes status.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

Figure KI 95: Percentages of kidneys recovered for transplant and not transplanted by donor diabetes status. Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

**Percentages of kidneys recovered for transplant and not transplanted by donor sex.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

Figure KI 96: Percentages of kidneys recovered for transplant and not transplanted by donor sex. Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

**Percentages of kidneys recovered for transplant and not transplanted by donor race and ethnicity.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 97: Percentages of kidneys recovered for transplant and not transplanted by donor race and ethnicity. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Percentages of kidneys recovered for transplant and not transplanted by donor hypertension status.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

Figure KI 98: Percentages of kidneys recovered for transplant and not transplanted by donor hypertension status. Percentages of kidneys not transplanted out of all kidneys recovered for transplant.

**Percentages of kidneys recovered for transplant and not transplanted by donor BMI.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. BMI, body mass index.

Figure KI 99: Percentages of kidneys recovered for transplant and not transplanted by donor BMI. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. BMI, body mass index.

**Percentages of kidneys recovered for transplant and not transplanted by donor terminal creatinine.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. Terminal creatinine refers to the final documented creatinine value before organ recovery.

Figure KI 100: Percentages of kidneys recovered for transplant and not transplanted by donor terminal creatinine. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. Terminal creatinine refers to the final documented creatinine value before organ recovery.

**Percentages of kidneys recovered for transplant and not transplanted by donor biopsy status.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. Kidneys are classified as biopsied if either of the donor's kidneys was biopsied.

Figure KI 101: Percentages of kidneys recovered for transplant and not transplanted by donor biopsy status. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. Kidneys are classified as biopsied if either of the donor’s kidneys was biopsied.

**Percentages of kidneys recovered for transplant and not transplanted by donor cause of death.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. CVA, cerebrovascular accident.

Figure KI 102: Percentages of kidneys recovered for transplant and not transplanted by donor cause of death. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. CVA, cerebrovascular accident.

**Percentages of kidneys recovered for transplant and not transplanted by donor HCV status.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. Donor HCV status was based on NAT and antibody tests. Ab, antibody; HCV, hepatitis C virus; NAT, nucleic acid test.

Figure KI 103: Percentages of kidneys recovered for transplant and not transplanted by donor HCV status. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. Donor HCV status was based on NAT and antibody tests. Ab, antibody; HCV, hepatitis C virus; NAT, nucleic acid test.

**Percentages of kidneys recovered for transplant and not transplanted, by donor risk of disease transmission.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. "Risk factors" refers to risk criteria for acute transmission of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus from the US Public Health Service Guideline.

Figure KI 104: Percentages of kidneys recovered for transplant and not transplanted, by donor risk of disease transmission. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. “Risk factors” refers to risk criteria for acute transmission of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus from the US Public Health Service Guideline.

**Percentages of kidneys recovered for transplant and not transplanted by DBD and DCD status.** Percentages of kidneys not transplanted out of all kidneys recovered for transplant. DBD, donation after brain death; DCD, donation after circulatory death.

Figure KI 105: Percentages of kidneys recovered for transplant and not transplanted by DBD and DCD status. Percentages of kidneys not transplanted out of all kidneys recovered for transplant. DBD, donation after brain death; DCD, donation after circulatory death.

Figure KI 106: Percentages of kidneys recovered for transplant and not transplanted by KDPI. Percentages of kidneys not transplanted out of all kidneys recovered for transplant, by KDPI classification. Conversion of kidney donor risk index to KDPI is done using the OPTN KDPI Mapping Tables. For donor organs recovered January through May, the cohort 2 years prior was used to assign KDPI; for donor organs recovered June through December, the cohort 1 year prior was used to assign KDPI. KDPI, kidney donor profile index.

Figure KI 107: Overall number of living kidney donors. As reported on the OPTN Living Donor Registration Form.

Figure KI 108: Number of living kidney donors by donor relation. As reported on the OPTN Living Donor Registration Form.

Figure KI 109: Living kidney donors by age. As reported on the OPTN Living Donor Registration Form.

Figure KI 110: Living kidney donors by sex. As reported on the OPTN Living Donor Registration Form.

**Living kidney donors by race and ethnicity.** As reported on the OPTN Living Donor Registration Form. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 111: Living kidney donors by race and ethnicity. As reported on the OPTN Living Donor Registration Form. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 112: Living kidney donors by BMI. Donor height and weight reported on the OPTN Living Donor Registration Form. BMI, body mass index.

Figure KI 113: Intended living kidney donor procedure type. As reported on the OPTN Living Donor Registration Form.

**New pediatric candidates added to the kidney transplant waiting list.** A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and were subsequently relisted are considered new. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 114: New pediatric candidates added to the kidney transplant waiting list. A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and were subsequently relisted are considered new. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**All pediatric candidates on the kidney transplant waiting list.** Candidates listed at more than one center are counted once per listing; age determined at first listing.

Figure KI 115: All pediatric candidates on the kidney transplant waiting list. Candidates listed at more than one center are counted once per listing; age determined at first listing.

**Distribution of pediatric candidates waiting for kidney transplant by age.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year. The 18+ category is for candidates who turned age 18 while waiting.

Figure KI 116: Distribution of pediatric candidates waiting for kidney transplant by age. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year. The 18+ category is for candidates who turned age 18 while waiting.

**Distribution of pediatric candidates waiting for kidney transplant by race and ethnicity.** Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included.

Figure KI 117: Distribution of pediatric candidates waiting for kidney transplant by race and ethnicity. Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included.

**Distribution of pediatric candidates waiting for kidney transplant by diagnosis.** Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 118: Distribution of pediatric candidates waiting for kidney transplant by diagnosis. Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

**Distribution of pediatric candidates waiting for kidney transplant by sex.** Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 119: Distribution of pediatric candidates waiting for kidney transplant by sex. Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of pediatric candidates waiting for kidney transplant by waiting time.** Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Candidates listed in the given year are considered to have been listed less than 1 year. Active and inactive candidates are included.

Figure KI 120: Distribution of pediatric candidates waiting for kidney transplant by waiting time. Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Candidates listed in the given year are considered to have been listed less than 1 year. Active and inactive candidates are included.

**Distribution of pediatric candidates waiting for kidney transplant by cPRA.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. cPRA is determined at the earliest of transplant, death, removal, or December 31 of the year. Missing indicates no unacceptable antigens were reported. Active and inactive candidates are included. cPRA, calculated panel-reactive antibody.

Figure KI 121: Distribution of pediatric candidates waiting for kidney transplant by cPRA. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. cPRA is determined at the earliest of transplant, death, removal, or December 31 of the year. Missing indicates no unacceptable antigens were reported. Active and inactive candidates are included. cPRA, calculated panel-reactive antibody.

**Distribution of pediatric candidates waiting for kidney transplant by blood type.** Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure KI 122: Distribution of pediatric candidates waiting for kidney transplant by blood type. Candidates waiting for transplant any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of pediatric candidates waiting for kidney transplant by years on dialysis.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on dialysis is computed as time from minimum of first end-stage renal disease service date or most recent graft failure to listing date or January 1 of the given year. Active and inactive candidates are included.

Figure KI 123: Distribution of pediatric candidates waiting for kidney transplant by years on dialysis. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on dialysis is computed as time from minimum of first end-stage renal disease service date or most recent graft failure to listing date or January 1 of the given year. Active and inactive candidates are included.

**Overall deceased donor kidney transplant rates among pediatric waitlist candidates.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure KI 124: Overall deceased donor kidney transplant rates among pediatric waitlist candidates. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor kidney transplant rates among pediatric waitlist candidates by age.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year. The 18+ category is for candidates who turned age 18 while waiting.

Figure KI 125: Deceased donor kidney transplant rates among pediatric waitlist candidates by age. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year. The 18+ category is for candidates who turned age 18 while waiting.

**Deceased donor kidney transplant rates among pediatric waitlist candidates by race and ethnicity.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 126: Deceased donor kidney transplant rates among pediatric waitlist candidates by race and ethnicity. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Deceased donor kidney transplant rates among pediatric waitlist candidates by cPRA.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. cPRA is determined at the later of listing date or January 1 of the given year. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure KI 127: Deceased donor kidney transplant rates among pediatric waitlist candidates by cPRA. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately. cPRA is determined at the later of listing date or January 1 of the given year. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**Deceased donor kidney transplant rates among pediatric waitlist candidates by blood type.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure KI 128: Deceased donor kidney transplant rates among pediatric waitlist candidates by blood type. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Three-year outcomes for newly listed pediatric candidates waiting for kidney transplant, 2019-2021.** Pediatric candidates who joined the waiting list in 2019-2021. Pediatric candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure KI 129: Three-year outcomes for newly listed pediatric candidates waiting for kidney transplant, 2019-2021. Pediatric candidates who joined the waiting list in 2019-2021. Pediatric candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Overall pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure KI 130: Overall pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by age.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year. The 18+ category is for candidates who turned age 18 while waiting.

Figure KI 131: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by age. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year. The 18+ category is for candidates who turned age 18 while waiting.

**Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by race and ethnicity.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

Figure KI 132: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by race and ethnicity. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American, Multiracial, and unreported categories.

**Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by diagnosis.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 133: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by diagnosis. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

**Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by cPRA.** Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. cPRA is determined at the later of listing date or January 1 of the given year. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure KI 134: Pretransplant mortality rates among pediatric candidates waitlisted for kidney transplant by cPRA. Pretransplant mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. cPRA is determined at the later of listing date or January 1 of the given year. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure KI 135: Overall pediatric kidney transplants. All pediatric kidney transplants, including retransplant and multiorgan.

Figure KI 136: Pediatric kidney transplants by donor type. All pediatric kidney transplants, including retransplant and multiorgan.

**Pediatric kidney transplants by recipient age.** All pediatric kidney transplants, including retransplant and multiorgan. Age is recipient age at transplant.

Figure KI 137: Pediatric kidney transplants by recipient age. All pediatric kidney transplants, including retransplant and multiorgan. Age is recipient age at transplant.

**Pediatric kidney transplants by diagnosis.** All pediatric kidney transplants, including retransplant and multiorgan. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 138: Pediatric kidney transplants by diagnosis. All pediatric kidney transplants, including retransplant and multiorgan. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 139: Pediatric kidney transplants by donor age. All pediatric kidney transplants, including retransplant and multiorgan.

**Number of living donor pediatric kidney transplants by donor relation.** As reported on the OPTN Living Donor Registration Form. All pediatric living kidney transplant recipients, including retransplant and multiorgan recipients.

Figure KI 140: Number of living donor pediatric kidney transplants by donor relation. As reported on the OPTN Living Donor Registration Form. All pediatric living kidney transplant recipients, including retransplant and multiorgan recipients.

**Pediatric kidney transplants by distance between donor and center.** All pediatric kidney transplants, including retransplant and multiorgan. Distance between donor and center is computed from donor hospital to the transplant center.

Figure KI 141: Pediatric kidney transplants by distance between donor and center. All pediatric kidney transplants, including retransplant and multiorgan. Distance between donor and center is computed from donor hospital to the transplant center.

**Percentages of pediatric deceased donor kidney transplants by years on dialysis.** All pediatric recipients of deceased donor kidneys, including multiorgan transplant recipients. Time on dialysis is computed as time from minimum of first end-stage renal disease service date or most recent graft failure to transplant date.

Figure KI 142: Percentages of pediatric deceased donor kidney transplants by years on dialysis. All pediatric recipients of deceased donor kidneys, including multiorgan transplant recipients. Time on dialysis is computed as time from minimum of first end-stage renal disease service date or most recent graft failure to transplant date.

Figure KI 143: Percentages of pediatric deceased donor kidney transplants by KDPI. All pediatric recipients of deceased donor kidneys, including multiorgan transplant recipients. Conversion of kidney donor risk index to KDPI is done using the OPTN KDPI Mapping Tables. For donor organs recovered January through May, the cohort 2 years prior was used to assign KDPI; for donor organs recovered June through December, the cohort 1 year prior was used to assign KDPI. Kidneys recovered en bloc are counted once. KDPI, kidney donor profile index.

**Percentages of pediatric kidney transplants from living donors by recipient age.** All pediatric living kidney transplant recipients, including retransplant and multiorgan recipients. Age is recipient age at transplant.

Figure KI 144: Percentages of pediatric kidney transplants from living donors by recipient age. All pediatric living kidney transplant recipients, including retransplant and multiorgan recipients. Age is recipient age at transplant.

**Number of centers performing pediatric and adult kidney transplants by center age mix.** Adult centers performed transplants only for recipients aged 18 years or older. Functionally adult centers performed 80% or more of transplants for adults (18+ years) and the remainder for adolescents aged 15-17 years. Pediatric centers performed most transplants for recipients aged 0-17 years and a small number for adults up to age 21 years. Mixed centers performed transplants for adults and children of any age group.

Figure KI 145: Number of centers performing pediatric and adult kidney transplants by center age mix. Adult centers performed transplants only for recipients aged 18 years or older. Functionally adult centers performed 80% or more of transplants for adults (18+ years) and the remainder for adolescents aged 15-17 years. Pediatric centers performed most transplants for recipients aged 0-17 years and a small number for adults up to age 21 years. Mixed centers performed transplants for adults and children of any age group.

**Percentages of pediatric kidney recipients by age at programs that perform five or fewer pediatric transplants annually.** Age groups are cumulative.

Figure KI 146: Percentages of pediatric kidney recipients by age at programs that perform five or fewer pediatric transplants annually. Age groups are cumulative.

**Induction agent use in pediatric kidney transplant recipients.** All pediatric kidney transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN.

Figure KI 147: Induction agent use in pediatric kidney transplant recipients. All pediatric kidney transplants, including retransplant and multiorgan. Immunosuppression at transplant reported to the OPTN.

**Type of induction agent use in pediatric kidney transplant recipients.** Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

Figure KI 148: Type of induction agent use in pediatric kidney transplant recipients. Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

**Immunosuppression regimen use in pediatric kidney transplant recipients.** All pediatric kidney transplants, including retransplant and multiorgan. Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

Figure KI 149: Immunosuppression regimen use in pediatric kidney transplant recipients. All pediatric kidney transplants, including retransplant and multiorgan. Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

**Total HLA A, B, and DR mismatches among pediatric kidney transplant recipients, 2020-2024.** All pediatric kidney transplants, including retransplant and multiorgan. Donor and recipient antigen matching is based on OPTN antigen values and split equivalences policy as of 2024. Unk, unknown.

Figure KI 150: Total HLA A, B, and DR mismatches among pediatric kidney transplant recipients, 2020-2024. All pediatric kidney transplants, including retransplant and multiorgan. Donor and recipient antigen matching is based on OPTN antigen values and split equivalences policy as of 2024. Unk, unknown.

**Delayed graft function among pediatric deceased donor kidney transplant recipients.** All pediatric recipients of deceased donor kidneys. Delayed graft function is defined as dialysis administered within the first 7 days posttransplant. DGF, delayed graft function.

Figure KI 151: Delayed graft function among pediatric deceased donor kidney transplant recipients. All pediatric recipients of deceased donor kidneys. Delayed graft function is defined as dialysis administered within the first 7 days posttransplant. DGF, delayed graft function.

**Delayed graft function among pediatric living donor kidney transplant recipients.** All pediatric recipients of living donor kidneys. Delayed graft function is defined as dialysis administered within the first 7 days posttransplant. DGF, delayed graft function.

Figure KI 152: Delayed graft function among pediatric living donor kidney transplant recipients. All pediatric recipients of living donor kidneys. Delayed graft function is defined as dialysis administered within the first 7 days posttransplant. DGF, delayed graft function.

**Graft failure among pediatric deceased donor kidney transplant recipients.** All pediatric recipients of deceased donor kidneys, including multiorgan transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods. Recipients are followed to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 6 months, 1, 3, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the prior outcomes prior to 6 months, 1, 3, 5, or 10 years, respectively.

Figure KI 153: Graft failure among pediatric deceased donor kidney transplant recipients. All pediatric recipients of deceased donor kidneys, including multiorgan transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods. Recipients are followed to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 6 months, 1, 3, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the prior outcomes prior to 6 months, 1, 3, 5, or 10 years, respectively.

**Graft failure among pediatric living donor kidney transplant recipients.** All pediatric recipients of living donor kidneys, including multiorgan transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods. Recipients are followed to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 6 months, 1, 3, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the prior outcomes prior to 6 months, 1, 3, 5, or 10 years, respectively.

Figure KI 154: Graft failure among pediatric living donor kidney transplant recipients. All pediatric recipients of living donor kidneys, including multiorgan transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods. Recipients are followed to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 6 months, 1, 3, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the prior outcomes prior to 6 months, 1, 3, 5, or 10 years, respectively.

**Percentages of patient deaths among pediatric kidney transplant recipients.** All pediatric recipients of deceased donor kidneys, including multiorgan transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods.

Figure KI 155: Percentages of patient deaths among pediatric kidney transplant recipients. All pediatric recipients of deceased donor kidneys, including multiorgan transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods.

**Graft survival among pediatric kidney transplant recipients, 2017-2019, by donor type.** Recipient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 156: Graft survival among pediatric kidney transplant recipients, 2017-2019, by donor type. Recipient survival estimated using unadjusted Kaplan-Meier methods.

**Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by age.** Recipient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

Figure KI 157: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by age. Recipient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

**Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by diagnosis.** Recipient survival estimated using unadjusted Kaplan-Meier methods. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 158: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by diagnosis. Recipient survival estimated using unadjusted Kaplan-Meier methods. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. Active and inactive candidates are included. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 159: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by KDPI. Recipient survival estimated using unadjusted Kaplan-Meier methods. Conversion of kidney donor risk index to KDPI is done using the OPTN KDPI Mapping Tables. For donor organs recovered January through May, the cohort 2 years prior was used to assign KDPI; for donor organs recovered June through December, the cohort 1 year prior was used to assign KDPI. KDPI, kidney donor profile index.

**Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by donor age.** Recipient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 160: Graft survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by donor age. Recipient survival estimated using unadjusted Kaplan-Meier methods.

**Overall patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019.** Recipient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 161: Overall patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019. Recipient survival estimated using unadjusted Kaplan-Meier methods.

**Patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by recipient age.** Recipient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

Figure KI 162: Patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by recipient age. Recipient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

**Patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by diagnosis.** Recipient survival estimated using unadjusted Kaplan-Meier methods. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 163: Patient survival among pediatric deceased donor kidney transplant recipients, 2017-2019, by diagnosis. Recipient survival estimated using unadjusted Kaplan-Meier methods. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

**Overall patient survival among pediatric living donor kidney transplant recipients, 2017-2019.** Recipient survival estimated using unadjusted Kaplan-Meier methods.

Figure KI 164: Overall patient survival among pediatric living donor kidney transplant recipients, 2017-2019. Recipient survival estimated using unadjusted Kaplan-Meier methods.

**Patient survival among pediatric living donor kidney transplant recipients, 2017-2019, by recipient age.** Recipient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

Figure KI 165: Patient survival among pediatric living donor kidney transplant recipients, 2017-2019, by recipient age. Recipient survival estimated using unadjusted Kaplan-Meier methods. Age is recipient age at transplant.

**Patient survival among pediatric living donor kidney transplant recipients, 2017-2019, by diagnosis.** Recipient survival estimated using unadjusted Kaplan-Meier methods. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

Figure KI 166: Patient survival among pediatric living donor kidney transplant recipients, 2017-2019, by diagnosis. Recipient survival estimated using unadjusted Kaplan-Meier methods. Diagnosis categories follow North American Pediatric Renal Trials and Collaborative Studies recommendations. CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerulosclerosis.

**Distribution of eGFR at 12 months posttransplant among pediatric deceased donor kidney transplant recipients.** Glomerular filtration rate (mL/min/1.73 m^2^) estimated using the bedside Schwartz equation, and computed by SRTR for patients alive with graft function at 12 months posttransplant. Equation: eGFR = 0.413*Height(cm)/Creatinine (mg/dL). eGFR, estimated glomerular filtration rate.

Figure KI 167: Distribution of eGFR at 12 months posttransplant among pediatric deceased donor kidney transplant recipients. Glomerular filtration rate (mL/min/1.73 m²) estimated using the bedside Schwartz equation, and computed by SRTR for patients alive with graft function at 12 months posttransplant. Equation: eGFR = 0.413*Height(cm)/Creatinine (mg/dL). eGFR, estimated glomerular filtration rate.

**Distribution of eGFR at 12 months posttransplant among pediatric living donor kidney transplant recipients.** Glomerular filtration rate (mL/min/1.73 m^2^) estimated using the bedside Schwartz equation and computed by SRTR for patients alive with graft function at 12 months posttransplant. Equation: eGFR = 0.413*Height(cm)/Creatinine (mg/dL). eGFR, estimated glomerular filtration rate.

Figure KI 168: Distribution of eGFR at 12 months posttransplant among pediatric living donor kidney transplant recipients. Glomerular filtration rate (mL/min/1.73 m²) estimated using the bedside Schwartz equation and computed by SRTR for patients alive with graft function at 12 months posttransplant. Equation: eGFR = 0.413*Height(cm)/Creatinine (mg/dL). eGFR, estimated glomerular filtration rate.

**Incidence of acute rejection by 1 year posttransplant among pediatric kidney transplant recipients by age.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Age is recipient age at transplant.

Figure KI 169: Incidence of acute rejection by 1 year posttransplant among pediatric kidney transplant recipients by age. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Age is recipient age at transplant.

**Incidence of acute rejection by 1 year posttransplant among pediatric kidney transplant recipients by induction agent use.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Immunosuppression at transplant reported to the OPTN.

Figure KI 170: Incidence of acute rejection by 1 year posttransplant among pediatric kidney transplant recipients by induction agent use. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Immunosuppression at transplant reported to the OPTN.

**Incidence of PTLD among pediatric kidney transplant recipients by recipient EBV status at transplant, 2013-2019.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or on the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure KI 171: Incidence of PTLD among pediatric kidney transplant recipients by recipient EBV status at transplant, 2013-2019. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or on the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Characteristic	2014 N	2014 Percent	2019 N	2019 Percent	2024 N	2024 Percent
Age (years)
18-34 years	10,115	9.4	8,364	8.2	7,294	7.6
35-49	28,125	26.1	24,357	24.0	22,940	23.8
50-64	46,815	43.5	44,109	43.5	41,509	43.0
65+	22,540	20.9	24,577	24.2	24,680	25.6
Sex
Female	43,195	40.1	38,603	38.1	36,285	37.6
Male	64,400	59.9	62,804	61.9	60,138	62.4
Race and ethnicity
Asian	9,117	8.5	9,876	9.7	9,353	9.7
Black	36,992	34.4	32,794	32.3	29,415	30.5
Hispanic	20,467	19.0	20,955	20.7	21,464	22.3
Multiracial	508	0.5	841	0.8	991	1.0
Native American	1,183	1.1	959	0.9	912	0.9
White	39,328	36.6	35,982	35.5	33,880	35.1
Unreported	0	0	0	0	408	0.4
Distance between candidate and center (miles)
<50 miles	71,238	66.2	67,082	66.2	62,859	65.2
50-<100	16,132	15.0	15,847	15.6	15,276	15.8
100-<150	7,787	7.2	6,953	6.9	6,927	7.2
150-<250	7,161	6.7	6,223	6.1	5,645	5.9
250+	4,613	4.3	4,832	4.8	5,092	5.3
Missing	664	0.6	470	0.5	624	0.6
All candidates
All candidates	107,595	100.0	101,407	100.0	96,423	100.0
OPTN/SRTR 2024 Annual Data Report

Characteristic	2014 N	2014 Percent	2019 N	2019 Percent	2024 N	2024 Percent
Diagnosis
Diabetes	37,996	35.3	39,073	38.5	38,361	39.8
Hypertension	26,014	24.2	21,491	21.2	19,116	19.8
Glomerulonephritis	15,572	14.5	14,565	14.4	12,689	13.2
Cystic kidney disease	9,026	8.4	8,793	8.7	8,301	8.6
Other/unknown	18,984	17.6	17,484	17.2	17,956	18.6
NA	3	0.0	1	0.0	0	0
Blood type
A	30,562	28.4	27,698	27.3	25,646	26.6
AB	2,979	2.8	2,538	2.5	2,370	2.5
B	17,745	16.5	16,929	16.7	15,552	16.1
O	56,309	52.3	54,242	53.5	52,855	54.8
cPRA
<1% or missing	66,815	62.1	63,395	62.5	54,866	56.9
1-<20%	8,454	7.9	9,409	9.3	10,757	11.2
20-<80%	15,807	14.7	16,524	16.3	20,259	21.0
80-<98%	6,960	6.5	5,705	5.6	5,014	5.2
98-100%	9,559	8.9	6,374	6.3	5,527	5.7
All candidates
All candidates	107,595	100.0	101,407	100.0	96,423	100.0
OPTN/SRTR 2024 Annual Data Report

Characteristic	2014 N	2014 Percent	2019 N	2019 Percent	2024 N	2024 Percent
Waiting time (years)
<1 year	31,600	29.4	33,280	32.8	36,000	37.3
1-<2	24,593	22.9	21,850	21.5	21,808	22.6
2-<3	17,479	16.2	14,542	14.3	14,206	14.7
3-<5	19,852	18.5	17,828	17.6	14,260	14.8
5+	14,071	13.1	13,907	13.7	10,149	10.5
Previous transplant
No prior transplant	92,057	85.6	89,470	88.2	86,137	89.3
Prior transplant	15,538	14.4	11,937	11.8	10,286	10.7
All candidates
All candidates	107,595	100.0	101,407	100.0	96,423	100.0
OPTN/SRTR 2024 Annual Data Report

Waiting list state	2022	2023	2024
Patients at start of year	95,933	95,203	94,733
Patients added during year	44,184	46,662	49,249
Patients removed during year	44,912	47,127	47,559
Patients at end of year	95,205	94,738	96,423
OPTN/SRTR 2024 Annual Data Report

Removal reason	2022	2023	2024
Deceased donor transplant	19,854	21,200	21,370
Living donor transplant	5,634	6,022	6,161
Transplant outside US	61	76	82
Patient died	4,734	4,049	3,743
Patient refused transplant	296	294	341
Improved, transplant not needed	269	329	308
Too sick for transplant	4,503	4,855	4,901
Other	9,324	10,048	10,363
Changed to kidney-pancreas list	219	239	229
Still on waiting list	18	15	61
OPTN/SRTR 2024 Annual Data Report

Characteristic	Deceased N	Deceased Percent	Living N	Living Percent	All N	All Percent
Recipient age (years)
18-34 years	1,901	8.9	1,006	16.3	2,907	10.5
35-49	4,988	23.2	1,637	26.5	6,625	24.0
50-64	8,639	40.2	2,254	36.4	10,893	39.4
65+	5,945	27.7	1,290	20.9	7,235	26.2
Sex
Female	8,725	40.6	2,234	36.1	10,959	39.6
Male	12,748	59.4	3,953	63.9	16,701	60.4
Race and ethnicity
Asian	1,753	8.2	471	7.6	2,224	8.0
Black	7,826	36.4	806	13.0	8,632	31.2
Hispanic	4,232	19.7	1,082	17.5	5,314	19.2
Multiracial	206	1.0	56	0.9	262	0.9
Native American	184	0.9	33	0.5	217	0.8
White	7,184	33.5	3,706	59.9	10,890	39.4
Unreported	88	0.4	33	0.5	121	0.4
Insurance
Private	5,949	27.7	3,388	54.8	9,337	33.8
Medicare	13,132	61.2	2,308	37.3	15,440	55.8
Medicaid	1,763	8.2	343	5.5	2,106	7.6
Other/unknown	629	2.9	148	2.4	777	2.8
Distance between recipient and center (miles)
<50 miles	14,059	65.5	3,968	64.1	18,027	65.2
50-<100	3,299	15.4	932	15.1	4,231	15.3
100-<150	1,483	6.9	433	7.0	1,916	6.9
150-<250	1,146	5.3	315	5.1	1,461	5.3
250+	1,230	5.7	431	7.0	1,661	6.0
Missing	256	1.2	108	1.7	364	1.3
Distance between donor and center (miles)
<50 miles	5,564	25.9	4,933	79.7	10,497	38.0
50-<150	5,253	24.5	92	1.5	5,345	19.3
150-<250	5,077	23.6	88	1.4	5,165	18.7
250-<500	2,655	12.4	231	3.7	2,886	10.4
500+	2,924	13.6	843	13.6	3,767	13.6
All recipients
All recipients	21,473	100.0	6,187	100.0	27,660	100.0
OPTN/SRTR 2024 Annual Data Report

Donor	Recipient	CMV	EBV	HBsAg	HCV antibody	HCV NAT
D-	R-	12.61	0.41	96.73	85.64	90.15
D-	R+	25.22	6.58	1.53	3.10	3.33
D-	R unk	0.45	0.27	1.46	1.47	1.53
D+	R-	18.19	4.50	0.21	9.18	4.63
D+	R+	41.61	84.58	0.01	0.48	0.25
D+	R unk	0.70	3.44	0.01	0.14	0.08
D unk	R-	0.34	0.01	0.06	0	0.04
D unk	R+	0.87	0.19	0.00	0	0.00
D unk	R unk	0.01	0.01	0.00	0	0
OPTN/SRTR 2024 Annual Data Report

Donor	Recipient	CMV	EBV
D-	R-	26.98	6.72
D-	R+	13.61	6.41
D-	R unk	0.91	0.18
D+	R-	37.02	37.93
D+	R+	19.24	46.88
D+	R unk	0.97	1.45
D unk	R-	0.97	0.12
D unk	R+	0.30	0.30
D unk	R unk	0	0
OPTN/SRTR 2024 Annual Data Report

Donor	Recipient	CMV	EBV
D-	R-	34.37	6.52
D-	R+	7.26	2.07
D-	R unk	1.33	0
D+	R-	34.37	56.30
D+	R+	17.63	33.04
D+	R unk	1.93	1.33
D unk	R-	2.37	0.59
D unk	R+	0.59	0.15
D unk	R unk	0.15	0
OPTN/SRTR 2024 Annual Data Report

**Table KI 7:** **Clinical characteristics of adult kidney transplant recipients, 2024.** Kidney transplant recipients, including retransplant and multiorgan recipients. Missing cPRA indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.
Characteristic	Deceased N	Deceased Percent	Living N	Living Percent	All N	All Percent
Diagnosis
Diabetes	7,569	35.2	1,543	24.9	9,112	32.9
Hypertension	5,013	23.3	958	15.5	5,971	21.6
Glomerulonephritis	2,896	13.5	1,391	22.5	4,287	15.5
Cystic kidney disease	1,866	8.7	1,042	16.8	2,908	10.5
Other/unknown	4,129	19.2	1,253	20.3	5,382	19.5
Blood type
A	7,211	33.6	2,370	38.3	9,581	34.6
AB	1,022	4.8	269	4.3	1,291	4.7
B	3,029	14.1	836	13.5	3,865	14.0
O	10,211	47.6	2,712	43.8	12,923	46.7
Time on dialysis (years)
None	3,212	15.0	1,967	31.8	5,179	18.7
<1 year	2,254	10.5	1,309	21.2	3,563	12.9
1-<3	4,981	23.2	1,656	26.8	6,637	24.0
3-<5	3,947	18.4	510	8.2	4,457	16.1
5+	7,079	33.0	745	12.0	7,824	28.3
cPRA
<1% or missing	11,594	54.0	3,936	63.6	15,530	56.1
1-<20%	2,217	10.3	749	12.1	2,966	10.7
20-<80%	4,062	18.9	1,227	19.8	5,289	19.1
80-<98%	2,083	9.7	210	3.4	2,293	8.3
98-100%	1,517	7.1	65	1.1	1,582	5.7
All recipients
All recipients	21,473	100.0	6,187	100.0	27,660	100.0
OPTN/SRTR 2024 Annual Data Report

**Table KI 10:** **Adult living donor kidney donor-recipient serology matching, 2022-2024.** Donor serology is reported on the OPTN Donor Registration Form and recipient serology on the OPTN Transplant Recipient Registration Form. There may be multiple fields per serology. Any evidence for a positive serology is treated as positive for that serology. Donor HCV NAT data are shown by recipient HCV antibody status. CMV, cytomegalovirus; EBV, Epstein-Barr virus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; NAT, nucleic acid test; unk, unknown.
Donor	Recipient	CMV	EBV	HBsAg	HCV antibody	HCV NAT
D-	R-	23.68	1.12	93.30	92.25	84.44
D-	R+	21.04	7.77	1.01	1.53	1.40
D-	R unk	0.93	0.23	3.28	3.40	2.79
D+	R-	17.04	5.38	0.51	0.74	0.08
D+	R+	31.87	80.44	0.01	0.03	0.01
D+	R unk	0.84	3.30	0	0.02	0.01
D unk	R-	2.03	0.12	1.78	1.90	10.37
D unk	R+	2.45	1.49	0.02	0.04	0.18
D unk	R unk	0.13	0.14	0.08	0.09	0.72
OPTN/SRTR 2024 Annual Data Report

**Table KI 12:** **Clinical characteristics of pediatric candidates on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024.** Candidates younger than 18 years at listing waiting for transplant on December 31 of the given year, regardless of first listing date. Missing cPRA indicates no unacceptable antigens were reported. CAKUT, congenital anomalies of the kidney and urinary tract; cPRA, calculated panel-reactive antibody; FSGS, focal segmental glomerulosclerosis.
Characteristic	2014 N	2014 Percent	2019 N	2019 Percent	2024 N	2024 Percent
Pediatric diagnosis
FSGS	169	11.6	147	9.5	143	7.3
Glomerulonephritis	154	10.5	135	8.7	142	7.3
CAKUT	489	33.4	558	35.9	659	33.7
Other/unknown	650	44.4	714	45.9	1,013	51.7
NA	1	0.1	0	0	1	0.1
Blood type
A	443	30.3	470	30.2	620	31.7
AB	39	2.7	41	2.6	53	2.7
B	237	16.2	231	14.9	299	15.3
O	744	50.9	812	52.3	986	50.4
cPRA
<1% or missing	902	61.7	1,080	69.5	1,267	64.7
1-<20%	92	6.3	103	6.6	194	9.9
20-<80%	186	12.7	193	12.4	288	14.7
80-<98%	108	7.4	70	4.5	103	5.3
98-100%	175	12.0	108	6.9	106	5.4
All candidates
All candidates	1,463	100.0	1,554	100.0	1,958	100.0
OPTN/SRTR 2024 Annual Data Report

**Table KI 13:** **Listing characteristics of pediatric candidates on the kidney transplant waiting list on December 31, 2014, December 31, 2019, and December 31, 2024.** Candidates younger than 18 years at listing waiting for transplant on December 31 of the given year, regardless of first listing date.
Characteristic	2014 N	2014 Percent	2019 N	2019 Percent	2024 N	2024 Percent
Waiting time (years)
<1 year	645	44.1	633	40.7	797	40.7
1-<2	314	21.5	327	21.0	361	18.4
2-<3	162	11.1	194	12.5	230	11.7
3-<5	160	10.9	205	13.2	248	12.7
5+	182	12.4	195	12.5	322	16.4
Previous transplant
No prior transplant	1,068	73.0	1,262	81.2	1,620	82.7
Prior transplant	395	27.0	292	18.8	338	17.3
All candidates
All candidates	1,463	100.0	1,554	100.0	1,958	100.0
OPTN/SRTR 2024 Annual Data Report